https://www.pharmaceutical-technology.com/data-insights/loncastuximab-tesirine-swedish-orphan-biovitrum-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2025-01-19T16:53:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/loncastuximab-tesirine-swedish-orphan-biovitrum-burkitt-lymphoma-likelihood-of-approval/ 2025-01-19T16:53:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nisevokitug-novartis-post-essential-thrombocythemia-myelofibrosis-post-et-mf-likelihood-of-approval/ 2024-09-09T01:44:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vudalimab-xencor-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T16:52:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiragolumab-genentech-usa-solid-tumor-likelihood-of-approval/ 2025-01-19T16:52:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luveltamab-tazevibulin-sutro-biopharma-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T16:52:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/loncastuximab-tesirine-swedish-orphan-biovitrum-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-19T16:52:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relatlimab-bristol-myers-squibb-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-19T16:52:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exagamglogene-autotemcel-crispr-therapeutics-sickle-cell-disease-likelihood-of-approval/ 2025-01-19T16:51:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nisevokitug-novartis-post-polycythemia-vera-myelofibrosis-ppv-mf-likelihood-of-approval/ 2024-09-09T01:43:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T16:51:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986178-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-09-09T01:43:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yson-001-yisheng-biopharma-solid-tumor-likelihood-of-approval/ 2024-04-19T00:28:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efineptakin-alfa-neoimmunetech-solid-tumor-likelihood-of-approval/ 2025-01-19T16:51:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/berzosertib-merck-solid-tumor-likelihood-of-approval/ 2024-07-05T01:29:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-19T16:45:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vobramitamab-duocarmazine-macrogenics-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-19T16:45:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nktr-255-nektar-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-19T16:44:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luveltamab-tazevibulin-sutro-biopharma-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T16:44:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-19T16:44:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2025-01-19T16:44:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitapivat-sulfate-agios-pharmaceuticals-beta-thalassaemia-likelihood-of-approval/ 2024-05-20T01:36:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/donafenib-tosylate-suzhou-zelgen-biopharmaceutical-solid-tumor-likelihood-of-approval/ 2024-09-09T01:41:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plogosertib-cyclacel-pharmaceuticals-leukemia-likelihood-of-approval/ 2025-01-19T16:44:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-dermatomyositis-likelihood-of-approval/ 2025-01-19T16:43:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-19T16:43:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alectinib-f-hoffmann-la-roche-solid-tumor-likelihood-of-approval/ 2025-01-19T16:43:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-likelihood-of-approval/ 2025-01-19T16:43:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ribociclib-succinate-novartis-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-19T16:43:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pac-1-vanquish-oncology-solid-tumor-likelihood-of-approval/ 2025-01-19T16:43:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-ovarian-cancer-likelihood-of-approval/ 2025-01-19T16:43:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rvu-120-ryvu-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-19T16:43:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-kaposi-sarcoma-likelihood-of-approval/ 2025-01-19T16:42:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-chronic-inflammatory-demyelinating-polyneuropathy-cidp-likelihood-of-approval/ 2025-01-19T16:42:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-bladder-cancer-likelihood-of-approval/ 2025-01-19T16:42:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-19T16:42:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T16:42:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-19T16:42:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-merkel-cell-carcinoma-likelihood-of-approval/ 2025-01-19T16:42:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2025-01-19T16:42:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-prostate-cancer-likelihood-of-approval/ 2025-01-19T16:42:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-gastric-cancer-likelihood-of-approval/ 2025-01-19T16:42:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-813160-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2025-01-19T16:41:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-basal-cell-carcinoma-basal-cell-epithelioma-likelihood-of-approval/ 2025-01-19T16:41:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-19T16:41:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/np-137-netris-pharma-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-19T16:41:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-skin-cancer-likelihood-of-approval/ 2025-01-19T16:41:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2025-01-19T16:41:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lurbinectedin-jazz-pharmaceuticals-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2025-01-19T16:41:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-19T16:41:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-19T16:40:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-19T16:40:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erdafitinib-johnson-johnson-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T16:40:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T16:40:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dabrafenib-mesylate-novartis-hairy-cell-leukemia-likelihood-of-approval/ 2025-01-19T16:40:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T16:40:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-19T16:39:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-19T16:39:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-19T16:39:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-lymphoblastic-lymphoma-likelihood-of-approval/ 2025-01-19T16:39:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rhenium-186re-obisbemeda-plus-therapeutics-head-and-neck-cancer-likelihood-of-approval/ 2024-07-05T06:18:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rhenium-186re-obisbemeda-plus-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-07-05T06:18:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imsa-101-immunesensor-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-20T02:16:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danvilostomig-systimmune-gastric-cancer-likelihood-of-approval/ 2025-01-20T02:16:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegargiminase-polaris-pharmaceuticals-gliosarcoma-likelihood-of-approval/ 2025-01-20T02:14:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegargiminase-polaris-pharmaceuticals-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-20T02:14:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lurbinectedin-jazz-pharmaceuticals-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2025-01-20T02:14:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/puxitatug-samrotecan-astrazeneca-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2024-09-09T03:30:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-20T02:10:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tocilizumab-chugai-pharmaceutical-follicular-lymphoma-likelihood-of-approval/ 2025-01-20T02:10:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amivantamab-johnson-johnson-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-19T18:26:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-metastatic-liver-cancer-likelihood-of-approval/ 2025-01-19T18:25:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-19T18:24:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2025-01-19T18:24:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-relapsed-multiple-myeloma-likelihood-of-approval/ 2025-01-19T18:24:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:24:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-19T18:23:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanzalintinib-fumarate-exelixis-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-19T18:23:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanzalintinib-fumarate-exelixis-laryngeal-cancer-likelihood-of-approval/ 2025-01-19T18:23:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanzalintinib-fumarate-exelixis-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-19T18:23:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanzalintinib-fumarate-exelixis-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-19T18:23:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iruplinalkib-qilu-pharmaceutical-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:22:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-lantern-pharma-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T18:22:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-primary-sjogren-s-syndrome-likelihood-of-approval/ 2025-01-19T18:22:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-hereditary-nonpolyposis-colon-cancer-likelihood-of-approval/ 2025-01-19T18:21:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-meningioma-likelihood-of-approval/ 2025-01-19T18:19:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-esophageal-cancer-likelihood-of-approval/ 2025-01-19T18:18:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-19T18:18:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T18:18:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-gastric-cancer-likelihood-of-approval/ 2025-01-19T18:18:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-ovarian-cancer-likelihood-of-approval/ 2025-01-19T18:18:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-colorectal-cancer-likelihood-of-approval/ 2025-01-19T18:18:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sy-5609-syros-pharmaceuticals-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-19T18:15:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-coherus-biosciences-chondrosarcoma-likelihood-of-approval/ 2025-01-19T18:15:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-coherus-biosciences-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-19T18:15:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-19T18:14:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiragolumab-genentech-usa-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-19T18:14:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-lung-cancer-likelihood-of-approval/ 2025-01-19T18:14:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efineptakin-alfa-neoimmunetech-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-19T18:14:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivarmacitinib-sulfate-jiangsu-hengrui-medicine-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2025-01-19T18:13:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/maplirpacept-pfizer-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-19T18:13:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceralasertib-astrazeneca-solid-tumor-likelihood-of-approval/ 2025-01-19T18:13:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pritumumab-nascent-biotech-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:11:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T18:11:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relatlimab-bristol-myers-squibb-melanoma-likelihood-of-approval/ 2025-01-19T18:11:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ttx-030-trishula-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-19T17:50:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/certepetide-lisata-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-19T17:50:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nisevokitug-novartis-solid-tumor-likelihood-of-approval/ 2024-09-09T02:01:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vobramitamab-duocarmazine-macrogenics-castration-resistant-prostate-cancer-crpc-likelihood-of-approval/ 2025-01-19T17:46:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sasanlimab-pfizer-ovarian-cancer-likelihood-of-approval/ 2024-07-05T05:14:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sasanlimab-pfizer-sarcomas-likelihood-of-approval/ 2024-07-05T05:14:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sasanlimab-pfizer-solid-tumor-likelihood-of-approval/ 2024-07-05T05:14:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spartalizumab-novartis-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-19T17:45:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spartalizumab-novartis-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-19T17:45:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/curcumin-doxorubicin-immix-biopharma-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-09-09T01:59:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2025-01-19T16:39:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-metastatic-biliary-tract-cancer-likelihood-of-approval-2/ 2024-12-25T16:56:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volrustomig-astrazeneca-cervical-cancer-likelihood-of-approval/ 2025-01-20T16:21:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/runimotamab-genentech-usa-solid-tumor-likelihood-of-approval/ 2025-01-20T16:21:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imvotamab-igm-biosciences-rheumatoid-arthritis-likelihood-of-approval/ 2025-01-20T16:21:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-20T16:21:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sor-007-nanology-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2025-01-20T16:21:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oleclumab-astrazeneca-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-20T16:20:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luveltamab-tazevibulin-sutro-biopharma-endometrial-cancer-likelihood-of-approval/ 2025-01-20T16:20:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/futibatinib-otsuka-pharmaceutical-solid-tumor-likelihood-of-approval/ 2025-01-20T16:20:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2025-01-20T16:20:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-20T16:20:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-osteosarcoma-likelihood-of-approval/ 2025-01-20T16:20:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-endometrial-cancer-likelihood-of-approval/ 2025-01-20T16:20:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-metastatic-melanoma-likelihood-of-approval/ 2025-01-20T16:19:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-pheochromocytoma-likelihood-of-approval/ 2025-01-20T16:19:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-melanoma-likelihood-of-approval/ 2025-01-20T16:19:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-colorectal-cancer-likelihood-of-approval/ 2025-01-20T16:19:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/baricitinib-eli-lilly-and-co-juvenile-arthritis-likelihood-of-approval/ 2025-01-20T16:19:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/helios-celmod-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-04-19T17:31:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/torl-3600-torl-biotherapeutics-solid-tumor-likelihood-of-approval/ 2025-01-20T16:19:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adrx-0706-adcentrx-therapeutics-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2025-01-20T16:19:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fx-909-flare-therapeutics-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2024-04-19T17:31:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fx-909-flare-therapeutics-solid-tumor-likelihood-of-approval/ 2024-04-19T17:31:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snp-318-scineuro-pharmaceuticals-alzheimer-s-disease-likelihood-of-approval/ 2024-01-08T18:36:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/askg-915-askgene-pharma-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2025-01-20T16:18:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vmt-a-net-perspective-therapeutics-medullary-thyroid-cancer-likelihood-of-approval/ 2025-01-20T16:18:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bdc-3042-bolt-biotherapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-07-05T06:28:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bdc-3042-bolt-biotherapeutics-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-07-05T06:28:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bdc-3042-bolt-biotherapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-07-05T06:28:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bdc-3042-bolt-biotherapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T06:28:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bdc-3042-bolt-biotherapeutics-solid-tumor-likelihood-of-approval/ 2024-07-05T06:28:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bdc-3042-bolt-biotherapeutics-head-and-neck-cancer-likelihood-of-approval/ 2024-07-05T06:28:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rmc-9805-revolution-medicines-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-20T16:18:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brigimadlin-boehringer-ingelheim-international-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2025-01-20T16:18:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brigimadlin-boehringer-ingelheim-international-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-20T16:17:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imvotamab-igm-biosciences-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-20T16:17:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-shanghai-junshi-biosciences-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-20T16:17:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-shanghai-junshi-biosciences-cervical-cancer-likelihood-of-approval/ 2025-01-20T16:17:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-deruxtecan-daiichi-sankyo-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-20T16:16:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spartalizumab-novartis-chronic-myelomonocytic-leukemia-cmml-likelihood-of-approval/ 2025-01-20T16:16:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spartalizumab-novartis-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-20T16:16:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spartalizumab-novartis-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-20T16:16:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spartalizumab-novartis-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-20T16:16:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nktr-255-nektar-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-20T16:16:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-idiopathic-inflammatory-myopathy-iim-likelihood-of-approval/ 2025-01-20T16:16:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-20T16:16:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-breast-cancer-likelihood-of-approval/ 2025-01-20T16:16:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ficlatuzumab-aveo-pharmaceuticals-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-20T16:16:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tolimidone-melior-pharmaceuticals-i-type-2-diabetes-likelihood-of-approval/ 2025-01-20T16:16:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naronapride-renexxion-corrosive-esophagitis-erosive-esophagitis-likelihood-of-approval/ 2025-01-20T16:16:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ozempic-novo-nordisk-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2025-01-20T16:15:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pln-101095-pliant-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-20T16:15:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imsa-101-immunesensor-therapeutics-solid-tumor-likelihood-of-approval-2/ 2024-12-25T18:13:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ph-762-phio-pharmaceuticals-metastatic-melanoma-likelihood-of-approval/ 2025-01-20T02:16:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danvilostomig-systimmune-gastric-cancer-likelihood-of-approval-2/ 2024-12-25T18:13:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegargiminase-polaris-pharmaceuticals-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval-2/ 2024-12-25T18:11:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegargiminase-polaris-pharmaceuticals-gliosarcoma-likelihood-of-approval-2/ 2024-12-25T18:10:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lurbinectedin-jazz-pharmaceuticals-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval-2/ 2024-12-25T18:10:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval-2/ 2024-12-25T18:07:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tocilizumab-chugai-pharmaceutical-follicular-lymphoma-likelihood-of-approval-2/ 2024-12-25T18:07:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zibotentan-astrazeneca-microvascular-angina-likelihood-of-approval/ 2024-07-05T06:09:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-20T02:10:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-merkel-cell-carcinoma-likelihood-of-approval/ 2025-01-20T02:10:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-20T02:10:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-nasopharyngeal-cancer-likelihood-of-approval/ 2025-01-20T02:10:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-esophageal-cancer-likelihood-of-approval/ 2025-01-20T02:10:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-20T02:10:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-endometrial-cancer-likelihood-of-approval/ 2025-01-19T18:28:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-solid-tumor-likelihood-of-approval/ 2025-01-19T18:28:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:27:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-gastric-cancer-likelihood-of-approval/ 2025-01-19T18:27:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-cervical-cancer-likelihood-of-approval/ 2025-01-19T18:27:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amivantamab-johnson-johnson-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval-2/ 2024-12-25T18:04:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-metastatic-liver-cancer-likelihood-of-approval-2/ 2024-12-25T18:03:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-04-19T16:58:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-04-19T16:58:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-04-19T16:58:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-peritoneal-cancer-likelihood-of-approval/ 2024-04-19T16:58:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-04-19T16:58:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-04-19T16:58:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-04-19T16:58:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-fallopian-tube-cancer-likelihood-of-approval/ 2024-04-19T16:58:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-thyroid-cancer-likelihood-of-approval/ 2024-04-19T16:58:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-19T16:58:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-endometrial-cancer-likelihood-of-approval/ 2024-04-19T16:58:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-solid-tumor-likelihood-of-approval/ 2024-04-19T16:58:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-sarcomas-likelihood-of-approval/ 2024-04-19T16:58:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-metastatic-melanoma-likelihood-of-approval/ 2024-04-19T16:58:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-19T16:58:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2024-04-19T16:57:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-09-09T02:23:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-09-09T02:23:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-09-09T02:23:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-09-09T02:23:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-09-09T02:22:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-09-09T02:22:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2024-09-09T02:22:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-peritoneal-cancer-likelihood-of-approval/ 2024-09-09T02:22:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-ureter-cancer-likelihood-of-approval/ 2024-09-09T02:22:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-urethral-cancer-likelihood-of-approval/ 2024-09-09T02:22:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-09-09T02:22:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-09-09T02:22:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-fallopian-tube-cancer-likelihood-of-approval/ 2024-09-09T02:22:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T02:22:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-endometrial-cancer-likelihood-of-approval/ 2024-09-09T02:22:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T02:22:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-bladder-cancer-likelihood-of-approval/ 2024-09-09T02:22:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-gastric-cancer-likelihood-of-approval/ 2024-09-09T02:22:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-refractory-multiple-myeloma-likelihood-of-approval-2/ 2024-12-25T17:58:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-relapsed-multiple-myeloma-likelihood-of-approval-2/ 2024-12-25T17:58:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:57:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-mantle-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:57:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval-2/ 2024-12-25T17:57:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lbl-007-beigene-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:23:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lbl-007-beigene-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:23:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanzalintinib-fumarate-exelixis-oral-cavity-mouth-cancer-likelihood-of-approval-2/ 2024-12-25T17:57:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanzalintinib-fumarate-exelixis-oropharyngeal-cancer-likelihood-of-approval-2/ 2024-12-25T17:57:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanzalintinib-fumarate-exelixis-laryngeal-cancer-likelihood-of-approval-2/ 2024-12-25T17:57:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanzalintinib-fumarate-exelixis-hypopharyngeal-cancer-likelihood-of-approval-2/ 2024-12-25T17:57:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iruplinalkib-qilu-pharmaceutical-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:56:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-lantern-pharma-pancreatic-cancer-likelihood-of-approval-2/ 2024-12-25T17:56:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-primary-sjogren-s-syndrome-likelihood-of-approval-2/ 2024-12-25T17:56:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-ureter-cancer-likelihood-of-approval/ 2025-01-19T18:22:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-urethral-cancer-likelihood-of-approval/ 2025-01-19T18:21:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-19T18:21:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T18:21:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-hereditary-nonpolyposis-colon-cancer-likelihood-of-approval-2/ 2024-12-25T17:55:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alg-apv-527-alligator-bioscience-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-19T18:20:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-meningioma-likelihood-of-approval-2/ 2024-12-25T17:53:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/grwd-5769-grey-wolf-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-19T17:51:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/grwd-5769-grey-wolf-therapeutics-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-19T17:51:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/grwd-5769-grey-wolf-therapeutics-cervical-cancer-likelihood-of-approval/ 2025-01-19T17:51:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ttx-030-trishula-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval-2/ 2024-12-25T17:34:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/certepetide-lisata-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval-2/ 2024-12-25T17:33:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vobramitamab-duocarmazine-macrogenics-castration-resistant-prostate-cancer-crpc-likelihood-of-approval-2/ 2024-12-25T17:28:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spartalizumab-novartis-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval-2/ 2024-12-25T17:27:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spartalizumab-novartis-pancreatic-ductal-adenocarcinoma-likelihood-of-approval-2/ 2024-12-25T17:27:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceralasertib-astrazeneca-solid-tumor-likelihood-of-approval-2/ 2024-12-25T17:46:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-pancreatic-cancer-likelihood-of-approval-2/ 2024-12-25T17:44:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pritumumab-nascent-biotech-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:44:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relatlimab-bristol-myers-squibb-melanoma-likelihood-of-approval-2/ 2024-12-25T17:44:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval-2/ 2024-12-25T17:51:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-esophageal-cancer-likelihood-of-approval-2/ 2024-12-25T17:51:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-gastric-cancer-likelihood-of-approval-2/ 2024-12-25T17:51:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-pancreatic-cancer-likelihood-of-approval-2/ 2024-12-25T17:51:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-colorectal-cancer-likelihood-of-approval-2/ 2024-12-25T17:51:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-ovarian-cancer-likelihood-of-approval-2/ 2024-12-25T17:51:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-and-ionis-challenge-alnylams-share-with-wainua-approval/ 2023-12-22T16:45:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/grupo-ferrer-internacional-gets-grant-for-inhaled-alprazolam-aerosol-for-treating-epilepsy-seizures/ 2023-12-22T16:42:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azenta-gets-grant-for-method-for-identifying-influenza-virus-recombinant-antibodies/ 2023-12-22T16:42:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amgen-gets-grant-for-crystal-formation-of-anti-pcsk9-antibody-using-specific-reagents/ 2023-12-22T16:41:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sanofi-gets-grant-for-drug-injection-device-with-enabled-and-sleep-states/ 2023-12-22T16:40:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovent-biologics-gets-grant-for-a-bispecific-antibody-for-treating-complex-diseases/ 2023-12-22T16:40:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/immunocore-gets-grant-for-method-of-obtaining-t-cell-receptor-for-peptide-antigen/ 2023-12-22T16:40:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipsen-gets-grant-for-treatment-of-diseases-with-compound-of-formula-i/ 2023-12-22T16:40:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biontech-gets-grant-for-patent-granted-for-antibody-against-disialoganglioside-gd2-in-cancer-treatment/ 2023-12-22T16:39:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apellis-pharmaceuticals-gets-grant-for-method-of-treating-chronic-respiratory-or-complement-mediated-disorders-using-complement-inhibitor/ 2023-12-22T16:39:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/johnson-johnson-gets-grant-for-expandable-apparatus-for-electrophysiological-sensing-with-staggered-electrodes/ 2023-12-22T16:39:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biocryst-pharmaceuticals-gets-grant-for-inhibitors-of-plasma-kallikrein/ 2023-12-22T16:39:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vertex-pharmaceuticals-gets-grant-for-prodrug-compounds-with-advantageous-properties-for-treating-disorders/ 2023-12-22T16:39:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agenus-gets-grant-for-patent-granted-for-t-cell-receptor-tcr-sequences/ 2023-12-22T16:39:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arcturus-therapeutics-gets-grant-for-patent-granted-for-nucleic-acid-molecules-encoding-viral-proteins/ 2023-12-22T16:39:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/corcept-therapeutics-gets-grant-for-crystalline-anhydrate-form-of-a-specific-compound/ 2023-12-22T16:38:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/viatris-gets-grant-for-patent-granted-for-compound-1-as-ep4-receptor-antagonist/ 2023-12-22T16:38:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/precision-biosciences-gets-grant-for-patent-granted-for-engineered-meganucleases-for-modifying-dystrophin-gene/ 2023-12-22T16:38:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ionis-pharmaceuticals-gets-grant-for-patent-granted-for-antisense-compound-to-treat-huntington-s-disease/ 2023-12-22T16:38:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/merus-gets-grant-for-bispecific-antibody-for-binding-egfr-and-cmet-receptors/ 2023-12-22T16:38:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inovio-pharmaceuticals-gets-grant-for-patent-granted-for-nucleic-acid-molecule-encoding-hpv-antigen/ 2023-12-22T16:37:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pacira-biosciences-gets-grant-for-method-of-treating-pain-by-injecting-liposome-encapsulated-bupivacaine-into-subarachnoid-space/ 2023-12-22T16:37:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bavarian-nordic-gets-grant-for-enhancing-expression-of-a-heterologous-gene-using-promoters-and-expression-cassettes/ 2023-12-22T16:37:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ligand-pharmaceuticals-gets-grant-for-method-of-preparing-a-compound-for-treating-inflammatory-disorders/ 2023-12-22T16:37:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axsome-therapeutics-gets-grant-for-the-patent-is-granted-for-a-method-of-treating-migraine/ 2023-12-22T16:36:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/santen-pharmaceutical-gets-grant-for-implantable-device-for-glaucoma-treatment-with-aqueous-humor-drainage/ 2023-12-22T16:36:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alnylam-pharmaceuticals-gets-grant-for-patent-granted-for-double-stranded-rnai-agent-targeting-tmprss6-gene/ 2023-12-22T16:36:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ascendis-pharma-gets-grant-for-pharmaceutical-composition-with-controlled-release-pth-compound/ 2023-12-22T16:36:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biogen-gets-grant-for-patent-granted-for-controlling-glycosylation-of-recombinant-protein-using-copper/ 2023-12-22T16:35:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enzo-biochem-gets-grant-for-reduced-background-multi-well-microtiter-plate-for-ligand-binding-assays/ 2023-12-22T16:35:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vanda-pharmaceuticals-gets-grant-for-the-patent-is-granted-for-a-process-to-prepare-highly-purified-tasimelteon/ 2023-12-22T16:35:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/coherus-biosciences-gets-grant-for-aseptic-packaging-method-for-sterile-pre-filled-injection-devices/ 2023-12-22T16:35:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/seagen-gets-grant-for-humanized-antibodies-for-treating-cancer-expressing-bcma/ 2023-12-22T16:34:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sarepta-therapeutics-gets-grant-for-conjugate-of-carrier-peptide-and-oligonucleotide-for-disease-treatment/ 2023-12-22T16:34:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/organovo-gets-grant-for-treatment-of-gastrointestinal-disease-using-farnesoid-x-receptor-agonists/ 2023-12-22T16:34:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amicus-therapeutics-gets-grant-for-patent-granted-for-a-method-of-metabolizing-glycogen-in-cells/ 2023-12-22T16:33:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xencor-gets-grant-for-bispecific-binding-agent-for-treating-cancer/ 2023-12-22T16:33:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/united-therapeutics-gets-grant-for-treating-interstitial-lung-disease-with-treprostinil-inhalation/ 2023-12-22T16:33:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lipocine-gets-grant-for-patent-granted-for-stable-pharmaceutical-composition-of-17-3-oxoandrost-4-en-17-yl-tridecanoate/ 2023-12-22T16:33:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chiesi-farmaceutici-gets-grant-for-delayed-release-tablets-for-treating-transfusional-iron-overload-in-thalassemia/ 2023-12-22T16:32:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/incyte-gets-grant-for-inhibitors-of-pi3k-for-treating-various-diseases/ 2023-12-22T16:32:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hca-healthcare-gets-grant-for-cassette-for-preparing-imaging-agent/ 2023-12-22T16:32:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/f-hoffmann-la-roche-gets-grant-for-combination-therapy-for-treating-hepatitis-b-virus-infection/ 2023-12-22T16:32:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sy-5609-syros-pharmaceuticals-pancreatic-ductal-adenocarcinoma-likelihood-of-approval-2/ 2024-12-25T17:47:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mannkind-gets-grant-for-medicament-delivery-device-with-automatic-pin-movement-after-time-delay/ 2023-12-22T16:31:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zoetis-gets-grant-for-cyclic-depsipeptide-compound-for-treating-endoparasitic-infection/ 2023-12-22T16:31:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-coherus-biosciences-soft-tissue-sarcoma-likelihood-of-approval-2/ 2024-12-25T17:47:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/intra-cellular-therapies-gets-grant-for-prodrugs-for-treating-central-nervous-system-disorders/ 2023-12-22T16:31:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-coherus-biosciences-chondrosarcoma-likelihood-of-approval-2/ 2024-12-25T17:47:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/grifols-gets-grant-for-device-for-handling-and-preparing-intravenous-medication-with-syringe/ 2023-12-22T16:31:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiragolumab-genentech-usa-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval-2/ 2024-12-25T17:47:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/moderna-gets-grant-for-variant-rna-polymerases-with-increased-transcription-efficiency-and-reduced-contaminants/ 2023-12-22T16:30:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-metastatic-renal-cell-carcinoma-likelihood-of-approval-2/ 2024-12-25T17:47:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shionogi-gets-grant-for-inhibitors-of-pde4-for-treating-inflammatory-and-other-diseases/ 2023-12-22T16:30:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jcr-pharmaceuticals-gets-grant-for-aqueous-preparation-for-stable-storage-of-protein-injection/ 2023-12-22T16:30:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/astrazeneca-gets-grant-for-treating-cll-with-a-btk-inhibitor/ 2023-12-22T16:30:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:47:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/galapagos-gets-grant-for-compound-inhibiting-adamts-for-treatment-of-inflammatory-conditions/ 2023-12-22T16:29:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efineptakin-alfa-neoimmunetech-triple-negative-breast-cancer-tnbc-likelihood-of-approval-2/ 2024-12-25T17:46:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bayer-gets-grant-for-dihydrooxydiazinone-compound-for-treating-hyperproliferative-diseases/ 2023-12-22T16:29:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bristol-myers-squibb-gets-grant-for-patent-granted-for-a-nucleic-acid-molecule-encoding-cd40-antibody/ 2023-12-22T16:29:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbvie-gets-grant-for-patent-granted-for-a-method-of-treating-spondyloarthropathy-with-a-tablet/ 2023-12-22T16:28:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/repotrectinib-bristol-myers-squibb-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2025-01-19T18:13:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/insmed-gets-grant-for-treating-pulmonary-hypertension-with-a-dry-powder-composition/ 2023-12-22T16:28:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sangamo-therapeutics-gets-grant-for-patent-granted-for-modifying-htt-gene-to-treat-huntington-s-disease/ 2023-12-22T16:28:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/repotrectinib-bristol-myers-squibb-central-nervous-system-cns-tumor-likelihood-of-approval/ 2025-01-19T18:13:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cytomx-therapeutics-gets-grant-for-patent-granted-for-activatable-antibodies-that-bind-cd166/ 2023-12-22T16:28:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jiangsu-hengrui-medicine-gets-grant-for-patent-granted-for-il-15-protein-complex-for-tumor-therapy/ 2023-12-22T16:27:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alpine-immune-sciences-gets-grant-for-variant-ctla-4-polypeptide-for-treatment-of-autoimmune-conditions/ 2023-12-22T16:27:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivarmacitinib-sulfate-jiangsu-hengrui-medicine-graft-versus-host-disease-gvhd-likelihood-of-approval-2/ 2024-12-25T17:46:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/maplirpacept-pfizer-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval-2/ 2024-12-25T17:46:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daiichi-sankyo-gets-grant-for-facile-synthesis-of-compounds-of-formula-2/ 2023-12-22T15:57:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/takeda-pharmaceutical-gets-grant-for-laser-processing-method-with-optimized-quality-control/ 2023-12-22T15:57:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ngm-biopharmaceuticals-gets-grant-for-patent-granted-for-antibodies-that-bind-human-complement-component-c3/ 2023-12-22T15:56:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bausch-health-gets-grant-for-implantable-corneal-and-intraocular-mask-with-controllable-opacity/ 2023-12-22T15:56:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mallinckrodt-gets-grant-for-monitoring-and-administering-nitric-oxide-with-lvads/ 2023-12-22T15:56:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nektar-therapeutics-gets-grant-for-conjugate-of-tlr-7-8-agonist-with-water-soluble-polymer/ 2023-12-22T15:56:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glenmark-pharmaceuticals-gets-grant-for-bispecific-antibody-binding-to-human-cd38-antigen/ 2023-12-22T15:55:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sage-therapeutics-gets-grant-for-prevention-and-treatment-of-various-conditions-using-specific-compounds/ 2023-12-22T15:55:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regeneron-pharmaceuticals-gets-grant-for-patent-granted-for-method-of-treating-allergies-with-il-4r-antagonist/ 2023-12-22T15:55:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jazz-pharmaceuticals-gets-grant-for-use-of-cbd-for-treating-seizures-in-dravet-syndrome/ 2023-12-22T15:55:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hanmi-science-gets-grant-for-anti-pd-1-anti-her2-bispecific-antibody-with-natural-igg-characteristics/ 2023-12-22T15:54:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bioatla-gets-grant-for-method-of-preparing-conditionally-active-antibodies-or-antibody-fragments/ 2023-12-22T15:54:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/novartis-gets-grant-for-an-apparatus-for-arresting-longitudinal-movement-of-a-plunger/ 2023-12-22T15:54:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/codexis-gets-grant-for-patent-granted-for-engineered-amylase-with-improved-stability-and-function/ 2023-12-22T15:54:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/evotec-gets-grant-for-lpxc-inhibitor-compound-for-treating-gram-negative-bacterial-infections/ 2023-12-22T15:53:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exelixis-gets-grant-for-crystalline-solid-form-of-compound-1/ 2023-12-22T15:53:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gilead-sciences-gets-grant-for-crystalline-form-of-compound-i/ 2023-12-22T15:53:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/merck-gets-grant-for-gpr35-modulators-for-treating-inflammatory-bowel-disease/ 2023-12-22T15:53:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neurocrine-biosciences-gets-grant-for-treating-classical-congenital-adrenal-hyperplasia-with-crf1-receptor-antagonist/ 2023-12-22T15:52:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/praxis-precision-medicines-gets-grant-for-neurological-disease-treatment-compounds/ 2023-12-22T15:52:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wuxi-biologics-cayman-gets-grant-for-raman-spectroscopy-integrated-perfusion-cell-culture-system/ 2023-12-22T15:52:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/krystal-biotech-gets-grant-for-the-patent-is-granted-for-a-pharmaceutical-composition-containing-a-recombinant-herpes-simplex-virus-type-1-hsv-1-and-a-transglutaminase-tgm-polypeptide/ 2023-12-22T15:51:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kymera-therapeutics-gets-grant-for-method-of-treating-autoimmune-autoinflammatory-diseases-and-hematological-malignancies/ 2023-12-22T15:51:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/allogene-therapeutics-gets-grant-for-the-patent-is-granted-for-isolated-antibodies-that-bind-anti-cd19-scfv/ 2023-12-22T15:51:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dyne-therapeutics-gets-grant-for-patent-granted-for-complexes-linking-muscle-targeting-agent-to-oligonucleotide/ 2023-12-22T15:51:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kinnate-biopharma-gets-grant-for-inhibitors-of-met-receptor-tyrosine-kinase/ 2023-12-22T15:50:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sosei-group-gets-grant-for-agonists-of-muscarinic-m1-and-or-m4-receptors/ 2023-12-22T15:50:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/angelini-gets-grant-for-a-patent-granted-for-a-synergistic-pain-treatment-composition/ 2023-12-22T15:50:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/precigen-gets-grant-for-a-patent-granted-for-chimeric-polypeptides-with-improved-antigen-binding/ 2023-12-22T15:50:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/argenx-gets-grant-for-patent-granted-for-combination-treatment-of-myeloid-malignancy/ 2023-12-22T15:49:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iovance-biotherapeutics-gets-grant-for-patent-granted-for-method-of-expanding-therapeutic-til-populations/ 2023-12-22T15:49:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/g1-therapeutics-gets-grant-for-patent-granted-for-method-of-reducing-chemotherapy-induced-myelosuppression/ 2023-12-22T15:49:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/teva-pharmaceutical-industries-gets-grant-for-method-of-testing-and-manufacturing-dry-powder-inhalers/ 2023-12-22T15:49:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/radius-health-gets-grant-for-polymorphic-forms-of-rad1901-2hcl-for-cancer-treatment/ 2023-12-22T15:48:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elanco-animal-health-gets-grant-for-patent-granted-for-improving-animal-reproductive-and-litter-performance/ 2023-12-22T15:48:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cidara-therapeutics-gets-grant-for-patent-granted-for-a-method-of-treating-invasive-candidiasis/ 2023-12-22T15:48:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/synlogic-gets-grant-for-genetically-engineered-bacteria-for-treating-hyperphenylalaninemia/ 2023-12-22T15:48:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/revolution-medicines-gets-grant-for-inhibiting-ras-proteins-for-cancer-treatment/ 2023-12-22T15:47:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denali-therapeutics-gets-grant-for-antibodies-that-specifically-bind-to-human-bace1-protein/ 2023-12-22T15:47:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/c4-therapeutics-gets-grant-for-cereblon-binders-for-degradation-of-ikaros-or-aiolos/ 2023-12-22T15:47:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bicycle-therapeutics-gets-grant-for-patent-granted-for-a-method-of-treating-retinal-disorders/ 2023-12-22T15:47:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pfizer-gets-grant-for-antifungal-pyridine-derivatives-for-treating-fungal-diseases/ 2023-12-22T15:46:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/seres-therapeutics-gets-grant-for-treatment-of-gastrointestinal-diseases-with-non-pathogenic-bacterial-spores/ 2023-12-22T15:46:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/astellas-pharma-gets-grant-for-method-for-sorting-renal-progenitor-cells-using-specific-markers/ 2023-12-22T15:46:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cellectis-gets-grant-for-patent-granted-for-method-to-produce-hiv-resistant-cells/ 2023-12-22T15:46:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lonza-group-gets-grant-for-patent-granted-for-a-recombinant-host-cell-with-reduced-flo8-protein-expression/ 2023-12-22T15:45:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ucb-gets-grant-for-a-method-of-reducing-seizures-using-fenfluramine-and-stiripentol/ 2023-12-22T15:45:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pathai-gets-grant-for-predicting-tissue-characteristics-for-pathology-images-using-machine-learning/ 2023-12-22T15:45:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wave-life-sciences-gets-grant-for-patent-granted-for-oligonucleotide-composition-with-specific-structural-characteristics/ 2023-12-22T15:44:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vir-biotechnology-gets-grant-for-antibodies-for-preventing-and-treating-lyssavirus-infections/ 2023-12-22T15:44:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/novan-files-patent-for-the-patent-is-filed-for-a-composition-for-treating-the-skin/ 2023-12-22T15:17:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amphastar-pharmaceuticals-files-patent-for-powder-formulation-for-nasal-administration-of-glucagon-for-hypoglycemia-treatment/ 2023-12-22T15:17:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arcturus-therapeutics-files-patent-for-the-patent-filed-is-for-compounds-and-their-pharmaceutically-acceptable-salts/ 2023-12-22T15:16:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/viatris-files-patent-for-r-5-e-2-pyrrolidin-3-ylvinyl-pyrimidine-mono-citrate-synthesis/ 2023-12-22T15:16:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sosei-group-files-patent-for-compound-for-treating-disorders-associated-with-glp-receptors/ 2023-12-22T15:16:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/genmab-files-patent-for-method-of-treating-chronic-lymphocytic-leukemia-using-bispecific-antibody/ 2023-12-22T15:15:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bicycle-therapeutics-files-patent-for-polypeptides-bound-to-molecular-scaffolds-for-disease-treatment/ 2023-12-22T15:15:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/haisco-pharmaceutical-group-files-patent-for-compound-for-treating-related-diseases-as-a-pb2-inhibitor/ 2023-12-22T15:15:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nurix-therapeutics-files-patent-for-the-patent-is-filed-for-a-method-of-treating-autoimmune-diseases-or-cancer-using-a-bifunctional-compound/ 2023-12-22T15:15:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pfizer-files-patent-for-topical-formulation-for-treating-inflammatory-disorders/ 2023-12-22T15:14:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sanofi-files-patent-for-recombinant-antibodies-for-inhibiting-b7-h4-in-disease-treatment/ 2023-12-22T15:14:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/innovent-biologics-files-patent-for-the-patent-filed-is-for-an-anti-cd73-antibody-or-antigen-binding-fragment/ 2023-12-22T15:14:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syros-pharmaceuticals-files-patent-for-oral-formulation-of-lyophilized-arsenic-for-treating-malignancies/ 2023-12-22T15:14:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipsen-files-patent-for-modified-botulinum-neurotoxin-a-bont-a-l-chain-protease-for-enhanced-cleavage-of-hsnap-23/ 2023-12-22T15:13:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biocryst-pharmaceuticals-files-patent-for-the-patent-is-filed-for-a-method-of-preparing-compound-2b1/ 2023-12-22T15:13:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/seres-therapeutics-files-patent-for-therapeutic-compositions-for-dysbiosis-treatment-using-ecobiotic-populations/ 2023-12-22T15:13:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/therapeutic-solutions-international-files-patent-for-the-patent-filed-is-for-a-method-of-treating-cognitive-dysfunction-associated-with-covid-19-and-inflammatory-conditions-using-a-specific-combinatio/ 2023-12-22T15:13:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azenta-files-patent-for-a-system-for-automatic-fault-diagnosis-in-devices/ 2023-12-22T15:12:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kobayashi-pharmaceutical-files-patent-for-auricle-heating-device-with-separate-left-and-right-devices/ 2023-12-22T15:12:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hisamitsu-pharmaceutical-files-patent-for-patch-for-inhibiting-degradation-of-asenapine-or-its-salt/ 2023-12-22T15:12:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amgen-files-patent-for-treatment-of-celiac-disease-and-non-celiac-gluten-sensitivity/ 2023-12-22T15:12:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/maruho-files-patent-for-film-forming-skin-composition-with-high-water-and-friction-resistance/ 2023-12-22T15:11:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/immunocore-files-patent-for-specific-binding-molecule-for-treating-hiv-infection/ 2023-12-22T15:11:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/scynexis-files-patent-for-injectable-composition-of-vesicles-encapsulating-enfumafungin-derived-antifungal-compounds/ 2023-12-22T15:11:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/endo-international-files-patent-for-the-patent-is-filed-for-a-pharmaceutical-composition-for-smoking-cessation/ 2023-12-22T15:10:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kodiak-sciences-files-patent-for-random-copolymers-containing-zwitterions-and-functional-agents/ 2023-12-22T15:10:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ac-immune-files-patent-for-antigenic-peptide-for-treating-synucleinopathies-with-specific-amino-acid-structure/ 2023-12-22T15:10:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/johnson-johnson-files-patent-for-an-apparatus-for-minimizing-rotation-of-a-staple-driver/ 2023-12-22T15:10:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/akebia-therapeutics-files-patent-for-small-molecule-inhibitors-of-phd/ 2023-12-22T15:09:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mirati-therapeutics-files-patent-for-inhibitors-of-sos1-activity-for-treating-cancer/ 2023-12-22T15:09:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/curis-files-patent-for-treating-diseases-and-disorders-using-compound-1/ 2023-12-22T15:09:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/astellas-pharma-files-patent-for-methods-for-generating-and-expanding-human-hemangio-colony-forming-cells/ 2023-12-22T15:09:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/corcept-therapeutics-files-patent-for-the-patent-filed-is-for-a-method-of-treating-non-acth-secreting-pancreatic-tumors-using-a-specific-combination-of-drugs/ 2023-12-22T15:08:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/epivax-files-patent-for-the-patent-is-filed-for-a-polypeptide-with-t-cell-epitopes/ 2023-12-22T15:08:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ionis-pharmaceuticals-files-patent-for-inhibiting-hsd17b13-expression-for-treating-associated-diseases/ 2023-12-22T15:08:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inovio-pharmaceuticals-files-patent-for-the-patent-is-filed-for-a-method-to-treat-or-prevent-vulvar-dysplasia-using-nucleic-acid-molecules-encoding-hpv-antigens/ 2023-12-22T15:07:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pacira-biosciences-files-patent-for-the-patent-filed-is-for-a-process-to-prepare-bupivacaine-liposomes/ 2023-12-22T15:07:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kineta-files-patent-for-treatment-of-neurological-disorders/ 2023-12-22T15:07:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cansino-biologics-files-patent-for-method-for-preparing-an-adenovirus-vector-vaccine-using-perfusion-culture/ 2023-12-22T15:07:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bavarian-nordic-files-patent-for-recombinant-modified-vaccinia-virus-ankara-encoding-covid-19-spike-protein/ 2023-12-22T15:06:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ligand-pharmaceuticals-files-patent-for-humanized-antibodies-with-ultralong-cdr3-and-their-uses/ 2023-12-22T15:06:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axsome-therapeutics-files-patent-for-solid-dosage-form-comprising-api-cyclodextrin-and-bicarbonate/ 2023-12-22T15:06:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eyepoint-pharmaceuticals-files-patent-for-compound-for-treating-vascular-disorders-and-increasing-cell-survival/ 2023-12-22T15:06:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cipla-files-patent-for-stable-extended-release-injectable-formulation-of-aripiprazole-for-schizophrenia/ 2023-12-22T15:05:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/santen-pharmaceutical-files-patent-for-pharmaceutical-formulation-for-treating-drug-refractory-glaucoma-or-ocular-hypertension/ 2023-12-22T15:05:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/assembly-biosciences-files-patent-for-the-patent-is-filed-for-pyrazole-carboxamide-compounds-for-treating-hepatitis-b/ 2023-12-22T15:05:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ascendis-pharma-files-patent-for-combination-of-cnp-agonist-and-biologically-active-moiety-for-growth-stimulation/ 2023-12-22T13:58:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ultragenyx-pharmaceutical-files-patent-for-the-patent-is-filed-for-a-modified-aav-cap-coding-sequence/ 2023-12-22T13:57:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chinook-therapeutics-files-patent-for-the-patent-is-filed-for-a-method-of-treating-diabetic-kidney-disease/ 2023-12-22T13:57:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ironwood-pharmaceuticals-files-patent-for-peptide-for-treating-gastrointestinal-disorders/ 2023-12-22T13:57:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cellectis-files-patent-for-the-patent-is-filed-for-an-mrna-molecule-encoding-a-pd-1-targeting-talen/ 2023-12-22T13:57:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/charles-river-laboratories-international-files-patent-for-hybrid-amebocyte-lysate-compositions-for-endotoxin-detection/ 2023-12-22T13:56:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/teladoc-health-files-patent-for-method-for-matching-telehealth-consult-requests-with-appropriate-providers/ 2023-12-22T13:56:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arvinas-files-patent-for-bifunctional-compounds-for-targeted-protein-degradation/ 2023-12-22T13:56:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biogen-files-patent-for-method-of-lowering-cholesterol-levels-using-compound-1/ 2023-12-22T13:56:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/deciphera-pharmaceuticals-files-patent-for-inhibiting-tie2-kinase-for-treating-vascular-anomalies/ 2023-12-22T13:55:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vanda-pharmaceuticals-files-patent-for-the-patent-is-filed-for-a-method-of-administering-tasimelteon-without-food/ 2023-12-22T13:55:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esperion-therapeutics-files-patent-for-method-of-lowering-ldl-c-using-crystalline-compound-formula-v/ 2023-12-22T13:55:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eiger-biopharmaceuticals-files-patent-for-method-of-treating-coronavirus-infection-with-pegylated-interferon-lambda-1a/ 2023-12-22T13:55:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/genexine-files-patent-for-pharmaceutical-formulation-comprising-modified-il-7-fusion-protein/ 2023-12-22T13:54:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/seagen-files-patent-for-detection-and-targeting-of-myeloid-derived-suppressor-cells-using-glycan-interacting-antibodies/ 2023-12-22T13:54:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sarepta-therapeutics-files-patent-for-treatment-of-muscle-viral-or-bacterial-infections-using-oligonucleotides-and-peptides/ 2023-12-22T13:54:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hu-group-files-patent-for-measurement-method-for-detecting-human-type-iv-collagen-7s-domain/ 2023-12-22T13:53:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/csl-files-patent-for-method-of-dispersing-agglomerated-material-in-influenza-protein-preparation/ 2023-12-22T13:53:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ono-pharmaceutical-files-patent-for-prophylactic-and-or-therapeutic-agent-for-idiopathic-interstitial-pneumonia/ 2023-12-22T13:53:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gc-files-patent-for-method-for-producing-varicella-zoster-virus-surface-protein-antigen/ 2023-12-22T13:53:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/angelini-files-patent-for-method-and-apparatus-for-producing-fluff-free-absorbent-cores/ 2023-12-22T13:52:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/simcere-pharmaceutical-group-files-patent-for-pharmaceutical-composition-comprising-aquaporin-inhibitor-and-meglumine/ 2023-12-22T13:52:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amicus-therapeutics-files-patent-for-improved-gene-therapy-vector-for-targeted-protein-expression/ 2023-12-22T13:52:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/united-therapeutics-files-patent-for-treatment-of-pulmonary-hypertension-by-inhalation-of-iloprost-and-treprostinil/ 2023-12-22T13:52:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chiesi-farmaceutici-files-patent-for-stable-formulation-of-tissue-type-plasminogen-activator-tpa/ 2023-12-22T13:52:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chong-kun-dang-pharmaceutical-files-patent-for-novel-donepezil-ether-palmitate-or-a-pharmaceutically-acceptable-salt/ 2023-12-22T13:52:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hca-healthcare-files-patent-for-dynamic-visualization-of-vasculature-using-3d-models-and-x-ray-imaging/ 2023-12-22T13:51:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rohto-pharmaceutical-files-patent-for-aqueous-ophthalmic-composition-comprising-delgocitinib-and-edetic-acid/ 2023-12-22T13:51:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/f-hoffmann-la-roche-files-patent-for-method-for-predicting-metabolic-state-of-cell-culture-using-machine-learning/ 2023-12-22T13:51:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sun-pharmaceutical-industries-files-patent-for-treatment-of-scalp-psoriasis-using-anti-il-23p19-antibody-hum13b8-b/ 2023-12-22T13:51:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trevena-files-patent-for-a-compound-for-modulating-delta-opioid-receptor-activity/ 2023-12-22T13:50:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zoetis-files-patent-for-injectable-pharmaceutical-compositions-with-effective-antimicrobial-preservation/ 2023-12-22T13:50:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/grifols-files-patent-for-method-for-reducing-frequency-of-anti-vegf-agent-administration/ 2023-12-22T13:49:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/moderna-files-patent-for-broad-spectrum-influenza-virus-rna-vaccines-and-methods-of-use/ 2023-12-22T13:49:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nippon-shinyaku-files-patent-for-novel-crystal-of-compound-b-with-specific-diffraction-angles/ 2023-12-22T13:49:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shionogi-files-patent-for-estimation-system-for-assessing-disorder-likelihood-using-brain-wave-and-mri-data/ 2023-12-22T13:48:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/galderma-files-patent-for-topical-composition-for-stimulating-hyaluronic-acid-production-in-skin/ 2023-12-22T13:48:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/twist-bioscience-files-patent-for-optimized-antibody-libraries-encoding-dkk1-antibodies/ 2023-12-22T13:48:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arrowhead-pharmaceuticals-files-patent-for-delivery-vehicle-for-targeted-gene-inhibition-in-skeletal-muscle-cells/ 2023-12-22T13:48:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selecta-biosciences-files-patent-for-synthetic-nanocarrier-composition-for-allergen-specific-immune-tolerance/ 2023-12-22T13:47:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inhibrx-files-patent-for-vhh-containing-polypeptides-that-bind-cd33/ 2023-12-22T13:47:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hansa-biopharma-files-patent-for-a-polypeptide-with-igg-cysteine-protease-activity-for-disease-treatment/ 2023-12-22T13:47:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/intra-cellular-therapies-files-patent-for-the-patent-is-filed-for-a-salt-or-crystal-form-of-a-substituted-heterocycle-fused-gamma-carboline/ 2023-12-22T13:49:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kissei-pharmaceutical-files-patent-for-the-patent-filed-is-for-a-succinate-salt-compound/ 2023-12-22T13:50:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mannkind-files-patent-for-a-patent-filed-for-an-inhalable-dry-powder-pharmaceutical-composition/ 2023-12-22T13:50:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cspc-pharmaceutical-group-files-patent-for-the-patent-is-filed-for-the-use-of-mitoxantrone-liposome-and-pegaspargase-in-treating-nk-t-cell-lymphoma/ 2023-12-22T13:52:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gedeon-richter-files-patent-for-new-pyrazolo-1-5-a-pyrimidine-derivatives-serving-as-gabab-receptor-positive-allosteric-modulators/ 2023-12-22T13:47:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chemomab-therapeutics-files-patent-for-treatment-of-fibrotic-inflammatory-diseases-with-anti-ccl24-monoclonal-antibody/ 2023-12-22T13:46:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bayer-files-patent-for-fluid-injection-system-with-fluid-verification-and-imaging-processing/ 2023-12-22T13:46:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bristol-myers-squibb-files-patent-for-method-of-treating-cutaneous-lupus-erythematosus-with-tlr7-inhibitor/ 2023-12-22T13:46:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/insmed-files-patent-for-extraction-of-neutrophil-serine-proteases-from-white-blood-cells/ 2023-12-22T13:45:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/indivior-files-patent-for-preventative-treatment-of-opioid-overdose-using-nalmefene-auto-injection/ 2023-12-22T13:45:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acer-therapeutics-files-patent-for-method-of-using-a-nk-antagonist-to-treat-vasomotor-symptoms-in-cancer-patients/ 2023-12-22T13:45:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/takara-files-patent-for-method-for-preparing-nucleic-acid-molecules-from-a-sample/ 2023-12-22T13:44:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sangamo-therapeutics-files-patent-for-the-patent-is-filed-for-a-polynucleotide-encoding-a-zinc-finger-nuclease/ 2023-12-22T13:41:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enanta-pharmaceuticals-files-patent-for-process-for-producing-a-sars-cov-2-3cl-pro-inhibitor/ 2023-12-22T13:44:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbvie-files-patent-for-the-patent-filed-is-for-a-process-to-prepare-a-pharmaceutical-composition-for-treating-arthritis/ 2023-12-22T13:42:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senju-pharmaceutical-files-patent-for-medicament-for-treating-or-preventing-corneal-endothelium-abnormality/ 2023-12-22T13:44:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zealand-pharma-files-patent-for-the-patent-is-filed-for-a4-7-antagonists-for-inflammatory-conditions/ 2023-12-22T13:43:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alpine-immune-sciences-files-patent-for-variant-ctla-4-polypeptides-with-amino-acid-substitutions-in-extracellular-domain/ 2023-12-22T13:44:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/astrazeneca-files-patent-for-the-patent-filed-is-for-a-method-of-treating-cancer/ 2023-12-22T13:40:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daiichi-sankyo-files-patent-for-injectable-composition-for-parenteral-nutrition-with-specific-mineral-content/ 2023-12-22T13:43:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bausch-health-files-patent-for-the-patent-is-filed-for-a-method-of-treating-onychomycosis/ 2023-12-22T13:41:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mallinckrodt-files-patent-for-therapeutic-gas-delivery-system-with-display-for-parameters/ 2023-12-22T13:43:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nektar-therapeutics-files-patent-for-conjugate-of-water-soluble-polymer-and-factor-viii-for-administration/ 2023-12-22T13:43:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glenmark-pharmaceuticals-files-patent-for-crystalline-form-of-a-compound-for-therapy/ 2023-12-22T13:43:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sage-therapeutics-files-patent-for-treatment-of-cns-related-disorders-with-compound-1/ 2023-12-22T13:42:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiziana-life-sciences-files-patent-for-treatment-and-prevention-of-coronavirus-using-anti-cd3-antibodies/ 2023-12-22T13:42:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regeneron-pharmaceuticals-files-patent-for-method-of-treating-muc16-expressing-cancer-using-bispecific-antibody/ 2023-12-22T13:42:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jazz-pharmaceuticals-files-patent-for-use-of-cbd-for-treating-seizures-associated-with-brain-injury/ 2023-12-22T13:42:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/huma-therapeutics-files-patent-for-estimating-interoception-level-using-heartbeat-sensor-and-user-interface/ 2023-12-22T13:41:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/celltrion-files-patent-for-stable-pharmaceutical-formulation-for-interleukin-6-receptor-antibody/ 2023-12-22T13:41:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hanmi-science-files-patent-for-the-patent-is-filed-for-a-method-of-treating-liver-disease/ 2023-12-22T13:41:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bioatla-files-patent-for-isolated-polypeptides-that-bind-to-cd46-protein/ 2023-12-22T13:36:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/novartis-files-patent-for-new-amino-pyrimidine-derivatives-for-treating-various-diseases/ 2023-12-22T13:36:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/harrow-health-files-patent-for-ophthalmic-pharmaceutical-composition-comprising-glycopeptide-and-aminoglycoside-antibiotics/ 2023-12-22T13:36:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mersana-therapeutics-files-patent-for-fully-human-monoclonal-antibodies-that-recognize-her2-receptor/ 2023-12-22T13:36:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-menarini-industrie-farmaceutiche-riunite-files-patent-for-a-system-for-handling-a-sample-with-ferromagnetic-particles/ 2023-12-22T13:35:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yuhan-files-patent-for-aminopyrimidine-derivative-with-selective-inhibitory-activity-against-protein-kinases/ 2023-12-22T13:35:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/marinus-pharmaceuticals-files-patent-for-injectable-ganaxolone-formulation-with-sulfobutyl-ether-cyclodextrin-for-treatment/ 2023-12-22T13:35:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ucb-files-patent-for-dihydrocyclopenta-isoquinoline-sulfonamide-derivatives-for-treating-ige-related-disorders/ 2023-12-22T13:34:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mochida-pharmaceutical-files-patent-for-a-sheet-like-material-for-preventing-adhesion/ 2023-12-22T13:34:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ocular-therapeutix-files-patent-for-intracameral-implant-for-treating-ocular-diseases/ 2023-12-22T13:34:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/merck-files-patent-for-inhibitors-of-nav1-8-channel-activity-for-treating-pain-and-itch-disorders/ 2023-12-22T13:34:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neurocrine-biosciences-files-patent-for-modulating-gpr52-activity-for-treating-neurological-diseases/ 2023-12-22T13:33:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/editas-medicine-files-patent-for-method-for-analyzing-activity-of-nucleases-using-droplet-emulsification/ 2023-12-22T13:33:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/proqr-therapeutics-files-patent-for-specific-editing-of-target-nucleotide-in-eukaryotic-cell-rna/ 2023-12-22T13:33:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/immunogen-files-patent-for-method-for-treating-hematologic-malignancy-using-anti-cd123-immunoconjugate/ 2023-12-22T13:33:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eloxx-pharmaceuticals-files-patent-for-macrolide-compounds-for-treating-infectious-diseases/ 2023-12-22T13:32:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/g1-therapeutics-files-patent-for-a-patent-filed-for-a-combination-therapy-for-cancer-treatment/ 2023-12-22T13:32:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shilpa-medicare-files-patent-for-pharmaceutical-composition-for-oral-delivery/ 2023-12-22T13:32:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shenzhen-hepalink-pharmaceutical-group-files-patent-for-composition-of-berberine-and-organic-acids-for-treating-diseases/ 2023-12-22T13:37:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/medigene-files-patent-for-enrichment-of-t-cells-expressing-recombinant-t-cell-receptors/ 2023-12-22T13:37:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eli-lilly-and-co-files-patent-for-ret-kinase-inhibitors/ 2023-12-22T13:36:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/teva-pharmaceutical-industries-files-patent-for-a-vial-adaptor-for-connecting-a-syringe-and-a-vial/ 2023-12-22T13:36:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/signal-lilly-searches-for-new-obesity-drugs-in-partnership-with-fauna-bio/ 2023-12-22T12:23:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/long-lasting-oral-therapy-developer-lyndra-secures-a-101m-series-e/ 2023-12-22T11:50:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ono-evqlv-develop-antibody-drugs/ 2023-12-22T12:23:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/immunoscape-eddc-tcr-based-therapeutics/ 2023-12-22T11:49:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jj-seeks-another-fda-label-for-rybrevant-in-nsclc/ 2024-01-03T15:01:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/2023-in-review-cancer-vaccines-dose-up-on-advances-with-tailored-approaches/ 2023-12-22T09:50:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/biontech-dualitybio-adc/ 2023-12-22T10:00:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-approves-takeda-livtencity/ 2023-12-22T09:56:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mei-pharma-files-patent-for-a-cancer-treatment-method-using-mitochondrial-and-bcl-2-inhibitors/ 2023-12-22T13:36:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lupin-files-patent-for-precipitation-process-for-amorphous-letermovir-suitable-for-pharmaceutical-formulations/ 2023-12-22T13:36:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-files-patent-for-p2x3-modulators-for-treatment-of-diseases-disorders-or-conditions/ 2023-12-22T13:35:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/scpharmaceuticals-files-patent-for-liquid-pharmaceutical-formulation-for-treating-congestion-edema-fluid-overload-or-hypertension/ 2023-12-22T13:35:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elanco-animal-health-files-patent-for-chewable-veterinary-composition-with-active-ingredient-and-carbonate-compound/ 2023-12-22T13:35:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaxcyte-files-patent-for-immunogenic-composition-for-inducing-immune-responses-against-gas-infections/ 2023-12-22T13:35:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avidity-biosciences-files-patent-for-method-of-delivering-oligonucleotide-for-treating-muscular-dystrophy/ 2023-12-22T13:34:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aldeyra-therapeutics-files-patent-for-treating-inflammatory-diseases-or-disorders/ 2023-12-22T13:34:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ose-immunotherapeutics-files-patent-for-il-7-variants-and-their-uses/ 2023-12-22T13:34:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crispr-therapeutics-files-patent-for-genome-editing-for-car-expression-and-immuno-oncology-gene-modulation/ 2023-12-22T13:34:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wave-life-sciences-files-patent-for-the-patent-is-filed-for-oligonucleotides-targeting-mapt-gene/ 2023-12-22T13:24:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/synlogic-files-patent-for-recombinant-bacteria-for-producing-d-lactate/ 2023-12-22T13:33:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/intellia-therapeutics-files-patent-for-gene-editing-method-for-treating-hereditary-angioedema-hae/ 2023-12-22T13:33:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eagle-pharmaceuticals-files-patent-for-the-patent-is-filed-for-a-method-of-treating-chronic-lymphocytic-leukemia-using-bendamustine-formulations-for-small-volume-intravenous-administration/ 2023-12-22T13:24:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spruce-biosciences-files-patent-for-treatment-of-polycystic-ovary-syndrome-with-crf1-antagonist/ 2023-12-22T13:33:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/codiak-biosciences-files-patent-for-method-for-loading-extracellular-vesicles-with-payload-molecules/ 2023-12-22T13:33:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relay-therapeutics-files-patent-for-inhibiting-shp2-phosphatase-activity-and-treating-associated-disorders/ 2023-12-22T13:32:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/praxis-precision-medicines-files-patent-for-pharmaceutical-composition-for-treating-neurological-diseases-or-disorders/ 2023-12-22T13:32:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/idorsia-pharmaceutical-files-patent-for-compound-of-formula-i-as-kv7-openers/ 2023-12-22T13:32:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/krystal-biotech-files-patent-for-recombinant-nucleic-acids-for-immunomodulatory-polypeptides-for-cancer-treatment/ 2023-12-22T13:32:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/veru-files-patent-for-method-of-treating-coronavirus-infections-using-anti-tubulin-compounds/ 2023-12-22T13:31:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bioxcel-therapeutics-files-patent-for-method-for-treating-castration-resistant-prostate-cancer-with-combination-therapy/ 2023-12-22T13:31:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/beam-therapeutics-files-patent-for-engineered-cas9-protein-for-nucleic-acid-targeting-and-manipulation/ 2023-12-22T13:31:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mind-medicine-mindmed-files-patent-for-composition-for-psychotherapeutic-treatment-with-r-enantiomer-of-mdma-or-mda/ 2023-12-22T13:30:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nautilus-biotechnology-files-patent-for-a-method-of-identifying-proteins-using-affinity-reagents/ 2023-12-22T13:30:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vertex-pharmaceuticals-files-patent-for-modulators-of-cystic-fibrosis-transmembrane-conductance-regulator-cftr/ 2023-12-22T13:30:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nabriva-therapeutics-files-patent-for-the-patent-is-filed-for-a-dosing-regimen-for-fosfomycin-treatment/ 2023-12-22T13:25:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/peptidream-files-patent-for-improving-binding-affinity-of-polypeptides-using-amino-acid-derivative/ 2023-12-22T13:30:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/medicinova-files-patent-for-method-of-treating-post-covid-condition-using-ibudilast/ 2023-12-22T13:29:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ptc-therapeutics-files-patent-for-recognition-element-for-splicing-modifier-compound/ 2023-12-22T13:29:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jcr-pharmaceuticals-files-patent-for-treatment-for-deficiency-in-a-l-iduronidase-in-the-cns/ 2023-12-22T13:29:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jiangsu-hengrui-medicine-files-patent-for-sulfur-containing-isoindoline-derivative-for-treatment-of-multiple-myeloma/ 2023-12-22T13:29:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ngm-biopharmaceuticals-files-patent-for-complex-for-treating-metabolism-and-body-weight-disorders/ 2023-12-22T13:28:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/codexis-files-patent-for-transaminase-polypeptides-capable-of-aminating-dicarbonyl-substrates/ 2023-12-22T13:28:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biolinerx-files-patent-for-method-of-treating-metastatic-pancreatic-adenocarcinoma-using-peptide-anti-pd-1-and-chemotherapy/ 2023-12-22T13:28:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/morphosys-files-patent-for-the-patent-is-filed-for-a-method-of-treating-thrombocythemia/ 2023-12-22T13:25:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/reata-pharmaceuticals-files-patent-for-c4-modified-oleanolic-acid-derivatives-for-il-17-related-diseases/ 2023-12-22T13:28:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/viking-therapeutics-files-patent-for-fxr-agonists-for-treating-fatty-liver-diseases/ 2023-12-22T13:27:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/recursion-pharmaceuticals-files-patent-for-treatment-of-lysosomal-storage-diseases-using-inhibitors-of-pkc-and-gsk3/ 2023-12-22T13:27:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pliant-therapeutics-files-patent-for-the-patent-is-filed-for-a-method-of-treating-fibrosis/ 2023-12-22T13:25:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/arcellx-files-patent-for-the-patent-is-filed-for-a-polypeptide-that-binds-cd-123/ 2023-12-22T13:25:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/macrogenics-files-patent-for-the-patent-is-filed-for-a-dosing-regimen-for-administering-a-pd-1-ctla-4-bispecific-molecule-for-cancer-treatment/ 2023-12-22T13:26:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/revance-therapeutics-files-patent-for-the-patent-filed-is-for-a-multi-tenant-loyalty-platform/ 2023-12-22T13:26:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pharma-mar-files-patent-for-combination-therapy-for-treating-solid-tumors-using-lurbinectedin-and-immune-checkpoint-inhibitor/ 2023-12-22T13:27:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biomarin-pharmaceutical-files-patent-for-targeted-therapeutic-fusion-protein-for-lysosomal-enzyme-delivery/ 2023-12-22T13:26:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/purdue-pharma-files-patent-for-tamper-resistant-opioid-analgesic-pharmaceutical-dosage-form/ 2023-12-22T13:26:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/heidelberg-pharma-files-patent-for-humanized-antibody-for-treating-prostate-cancer-and-neurological-diseases/ 2023-12-22T06:08:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xencor-files-patent-for-novel-heterodimeric-proteins-or-heterodimeric-antibodies/ 2023-12-22T06:07:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/poseida-therapeutics-files-patent-for-the-patent-is-filed-for-directing-proteins-to-specific-loci-in-a-genome/ 2023-12-22T06:07:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oncorus-files-patent-for-recombinant-oncolytic-herpes-simplex-virus-for-cancer-treatment/ 2023-12-22T06:07:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-pleomorphic-liposarcoma-likelihood-of-approval-2/ 2024-12-25T17:44:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-angiosarcoma-likelihood-of-approval-2/ 2024-12-25T17:43:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-chondrosarcoma-likelihood-of-approval-2/ 2024-12-25T17:43:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/guselkumab-johnson-johnson-crohn-s-disease-regional-enteritis-likelihood-of-approval-2/ 2024-12-25T17:43:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-kaposi-sarcoma-likelihood-of-approval-2/ 2024-12-25T17:43:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-esophageal-cancer-likelihood-of-approval-2/ 2024-12-25T17:43:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erdafitinib-johnson-johnson-squamous-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:43:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kyv-101-kyverna-therapeutics-lupus-nephritis-likelihood-of-approval-2/ 2024-12-25T17:43:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-chronic-lymphocytic-leukemia-cll-likelihood-of-approval-2/ 2024-12-25T17:41:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regorafenib-bayer-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval-2/ 2024-12-25T17:41:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-9592-astrazeneca-non-small-cell-lung-carcinoma-likelihood-of-approval/ 2025-01-19T18:07:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asp-3082-astellas-pharma-pancreatic-ductal-adenocarcinoma-likelihood-of-approval-2/ 2024-12-25T17:40:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986406-bristol-myers-squibb-squamous-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:40:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986406-bristol-myers-squibb-pancreatic-ductal-adenocarcinoma-likelihood-of-approval-2/ 2024-12-25T17:40:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amg-193-amgen-metastatic-biliary-tract-cancer-likelihood-of-approval-2/ 2024-12-25T17:39:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pyx-201-pyxis-oncology-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-07-05T05:44:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pyx-201-pyxis-oncology-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-07-05T05:44:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pyx-201-pyxis-oncology-soft-tissue-sarcoma-likelihood-of-approval/ 2024-07-05T05:44:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pyx-201-pyxis-oncology-thyroid-cancer-likelihood-of-approval/ 2024-07-05T05:44:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pyx-201-pyxis-oncology-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T05:44:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pyx-201-pyxis-oncology-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2024-07-05T05:44:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pyx-201-pyxis-oncology-solid-tumor-likelihood-of-approval/ 2024-07-05T05:44:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pyx-201-pyxis-oncology-hepatocellular-carcinoma-likelihood-of-approval/ 2024-07-05T05:44:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pyx-201-pyxis-oncology-metastatic-breast-cancer-likelihood-of-approval/ 2024-07-05T05:44:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pyx-201-pyxis-oncology-ovarian-cancer-likelihood-of-approval/ 2024-07-05T05:44:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/janx-008-janux-therapeutics-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-19T18:04:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/janx-008-janux-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-19T18:04:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/janx-008-janux-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:04:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/janx-008-janux-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-19T18:04:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diakine-dk210-egfr-deka-biosciences-skin-cancer-likelihood-of-approval/ 2025-01-19T18:04:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diakine-dk210-egfr-deka-biosciences-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:04:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diakine-dk210-egfr-deka-biosciences-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2025-01-19T18:04:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diakine-dk210-egfr-deka-biosciences-solid-tumor-likelihood-of-approval/ 2025-01-19T18:03:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diakine-dk210-egfr-deka-biosciences-bladder-cancer-likelihood-of-approval/ 2025-01-19T18:03:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diakine-dk210-egfr-deka-biosciences-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T18:03:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diakine-dk210-egfr-deka-biosciences-head-and-neck-cancer-likelihood-of-approval/ 2025-01-19T18:03:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diakine-dk210-egfr-deka-biosciences-colorectal-cancer-likelihood-of-approval/ 2025-01-19T18:03:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ustekinumab-biosimilar-celltrion-ulcerative-colitis-likelihood-of-approval/ 2025-01-19T18:02:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-rectal-cancer-likelihood-of-approval/ 2025-01-19T18:02:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-19T18:02:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-gastric-cancer-likelihood-of-approval/ 2025-01-19T18:02:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T18:02:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bb-1701-bliss-biopharmaceutical-hangzhou-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval-2/ 2024-12-25T17:36:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bb-1701-bliss-biopharmaceutical-hangzhou-bladder-cancer-likelihood-of-approval-2/ 2024-12-25T17:36:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bb-1701-bliss-biopharmaceutical-hangzhou-colon-cancer-likelihood-of-approval-2/ 2024-12-25T17:36:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ava-6000-avacta-life-sciences-metastatic-biliary-tract-cancer-likelihood-of-approval-2/ 2024-12-25T17:35:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ava-6000-avacta-life-sciences-pancreatic-ductal-adenocarcinoma-likelihood-of-approval-2/ 2024-12-25T17:35:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ava-6000-avacta-life-sciences-solid-tumor-likelihood-of-approval-2/ 2024-12-25T17:35:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imsa-101-immunesensor-therapeutics-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval-2/ 2024-12-25T17:35:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabometyx-exelixis-neuroendocrine-gastroenteropancreatic-tumors-gep-net-likelihood-of-approval-2/ 2024-12-25T17:34:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nktr-255-nektar-therapeutics-colon-carcinoma-likelihood-of-approval-2/ 2024-12-25T17:27:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nktr-255-nektar-therapeutics-anal-cancer-likelihood-of-approval-2/ 2024-12-25T17:27:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nktr-255-nektar-therapeutics-cervical-cancer-likelihood-of-approval-2/ 2024-12-25T17:27:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivosidenib-les-laboratoires-servier-low-grade-glioma-likelihood-of-approval-2/ 2024-12-25T17:26:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivosidenib-les-laboratoires-servier-chondrosarcoma-likelihood-of-approval-2/ 2024-12-25T17:26:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alg-apv-527-alligator-bioscience-solid-tumor-likelihood-of-approval/ 2025-01-19T17:43:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syd-3521-byondis-esophageal-cancer-likelihood-of-approval/ 2024-09-09T01:58:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syd-3521-byondis-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T01:58:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syd-3521-byondis-pancreatic-cancer-likelihood-of-approval/ 2024-09-09T01:58:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syd-3521-byondis-colorectal-cancer-likelihood-of-approval/ 2024-09-09T01:58:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-antibody-mediated-rejection-amr-likelihood-of-approval-2/ 2024-12-25T17:25:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:25:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imifoplatin-promontory-therapeutics-thymoma-thymic-epithelial-tumor-likelihood-of-approval-2/ 2024-12-25T17:25:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imifoplatin-promontory-therapeutics-pancreatic-cancer-likelihood-of-approval-2/ 2024-12-25T17:25:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imifoplatin-promontory-therapeutics-ovarian-cancer-likelihood-of-approval-2/ 2024-12-25T17:25:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-lung-adenocarcinoma-likelihood-of-approval-2/ 2024-12-25T17:24:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lutikizumab-abbvie-hidradenitis-suppurativa-likelihood-of-approval-2/ 2024-12-25T17:24:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-ureter-cancer-likelihood-of-approval-2/ 2024-12-25T17:24:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-anal-cancer-likelihood-of-approval-2/ 2024-12-25T17:24:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nadunolimab-cantargia-metastatic-biliary-tract-cancer-likelihood-of-approval-2/ 2024-12-25T17:24:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brolucizumab-novartis-polypoidal-choroidal-vasculopathy-likelihood-of-approval-2/ 2024-12-25T17:23:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-carcinoma-of-unknown-primary-occult-primary-tumor-cancer-of-unknown-primary-likelihood-of-approval-2/ 2024-12-25T17:23:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval-2/ 2024-12-25T17:23:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-gliosarcoma-likelihood-of-approval-2/ 2024-12-25T17:23:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-uterine-cancer-likelihood-of-approval-2/ 2024-12-25T17:23:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-adrenocortical-carcinoma-adrenal-cortex-cancer-likelihood-of-approval-2/ 2024-12-25T17:23:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-metastatic-colorectal-cancer-likelihood-of-approval-2/ 2024-12-25T17:23:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dupilumab-regeneron-pharmaceuticals-gastritis-likelihood-of-approval-2/ 2024-12-25T17:23:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dupilumab-regeneron-pharmaceuticals-gastroenteritis-likelihood-of-approval-2/ 2024-12-25T17:23:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dupilumab-regeneron-pharmaceuticals-bullous-pemphigoid-likelihood-of-approval-2/ 2024-12-25T17:23:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dupilumab-regeneron-pharmaceuticals-systemic-sclerosis-scleroderma-likelihood-of-approval-2/ 2024-12-25T17:23:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abemaciclib-eli-lilly-and-co-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval-2/ 2024-12-25T17:22:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abemaciclib-eli-lilly-and-co-metastatic-breast-cancer-likelihood-of-approval-2/ 2024-12-25T17:22:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abemaciclib-eli-lilly-and-co-breast-cancer-likelihood-of-approval-2/ 2024-12-25T17:22:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-pediatric-diffuse-intrinsic-pontine-glioma-likelihood-of-approval-2/ 2024-12-25T17:22:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-high-grade-glioma-likelihood-of-approval-2/ 2024-12-25T17:22:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/levosimendan-tenax-therapeutics-pulmonary-hypertension-likelihood-of-approval/ 2024-07-05T01:53:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tipiracil-hydrochloride-trifluridine-taiho-oncology-rectal-cancer-likelihood-of-approval-2/ 2024-12-25T17:21:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-penile-cancer-likelihood-of-approval-2/ 2024-12-25T17:21:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/carfilzomib-amgen-multiple-myeloma-kahler-disease-likelihood-of-approval-2/ 2024-12-25T17:20:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tocilizumab-f-hoffmann-la-roche-diffuse-large-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:20:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fruquintinib-takeda-pharmaceutical-angiosarcoma-likelihood-of-approval-2/ 2024-12-25T17:20:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fruquintinib-takeda-pharmaceutical-metastatic-pancreatic-cancer-likelihood-of-approval-2/ 2024-12-25T17:20:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbp-1019-coherent-biopharma-esophageal-cancer-likelihood-of-approval-2/ 2024-12-25T17:19:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbp-1019-coherent-biopharma-pancreatic-cancer-likelihood-of-approval-2/ 2024-12-25T17:19:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbp-1019-coherent-biopharma-colorectal-cancer-likelihood-of-approval-2/ 2024-12-25T17:19:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbp-1019-coherent-biopharma-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:19:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbp-1019-coherent-biopharma-breast-cancer-likelihood-of-approval-2/ 2024-12-25T17:19:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/baricitinib-eli-lilly-and-co-polymyalgia-rheumatica-pmr-likelihood-of-approval-2/ 2024-12-25T17:18:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-osteosarcoma-likelihood-of-approval-2/ 2024-12-25T17:18:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:18:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-t-cell-leukemia-likelihood-of-approval-2/ 2024-12-25T17:18:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-primary-systemic-amyloidosis-likelihood-of-approval-2/ 2024-12-25T17:18:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:18:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-systemic-lupus-erythematosus-likelihood-of-approval-2/ 2024-12-25T17:18:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spartalizumab-novartis-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval-2/ 2024-12-25T17:18:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ubidecarenone-bpgbio-glioblastoma-multiforme-gbm-likelihood-of-approval-2/ 2024-12-25T17:17:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-natural-killer-cell-lymphomas-likelihood-of-approval-2/ 2024-12-25T17:17:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elinzanetant-bayer-vasomotor-symptoms-of-menopause-hot-flashes-likelihood-of-approval/ 2025-01-19T17:19:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regorafenib-bayer-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval-2/ 2024-12-25T17:17:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regorafenib-bayer-esophageal-cancer-likelihood-of-approval-2/ 2024-12-25T17:17:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regorafenib-bayer-gastric-cancer-likelihood-of-approval-2/ 2024-12-25T17:17:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-precursor-b-cell-lymphoblastic-leukemia-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:17:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-high-grade-glioma-likelihood-of-approval-2/ 2024-12-25T17:17:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-rhabdomyosarcoma-likelihood-of-approval-2/ 2024-12-25T17:17:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:17:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-ewing-sarcoma-likelihood-of-approval-2/ 2024-12-25T17:17:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-metastatic-melanoma-likelihood-of-approval-2/ 2024-12-25T17:17:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-colorectal-cancer-likelihood-of-approval-2/ 2024-12-25T17:16:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-0228-brightgene-bio-medical-technology-gastric-cancer-likelihood-of-approval-2/ 2024-12-25T17:16:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-relapsed-acute-myeloid-leukemia-likelihood-of-approval-2/ 2024-12-25T17:16:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-myeloproliferative-disorders-likelihood-of-approval-2/ 2024-12-25T17:16:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-solid-tumor-likelihood-of-approval-2/ 2024-12-25T17:16:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval-2/ 2024-12-25T17:16:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-19T17:17:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-colorectal-cancer-likelihood-of-approval-2/ 2024-12-25T17:15:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-peritoneal-cancer-likelihood-of-approval-2/ 2024-12-25T17:15:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-amyloidosis-likelihood-of-approval-2/ 2024-12-25T17:15:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-0228-brightgene-bio-medical-technology-solid-tumor-likelihood-of-approval-2/ 2024-12-25T17:15:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-0228-brightgene-bio-medical-technology-metastatic-pancreatic-cancer-likelihood-of-approval-2/ 2024-12-25T17:15:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bis-5-l-l-biopharma-colorectal-cancer-likelihood-of-approval/ 2025-01-19T17:00:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-0228-brightgene-bio-medical-technology-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:14:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ava-6000-avacta-life-sciences-metastatic-colorectal-cancer-likelihood-of-approval-2/ 2024-12-25T17:14:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hcw-9218-hcw-biologics-solid-tumor-likelihood-of-approval-2/ 2024-12-25T17:14:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-9592-astrazeneca-solid-tumor-likelihood-of-approval/ 2025-01-19T17:00:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/maat-033-maat-pharma-chemotherapy-effects-likelihood-of-approval-2/ 2024-12-25T17:13:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tti-101-tvardi-therapeutics-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-19T16:59:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bis-5-l-l-biopharma-ovarian-cancer-likelihood-of-approval/ 2025-01-19T16:58:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tak-500-takeda-pharmaceutical-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T16:58:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T16:58:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hhcyh-33-shanghai-haihe-biopharma-solid-tumor-likelihood-of-approval/ 2024-06-14T01:33:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omn-6-omnix-medical-ventilator-associated-pneumonia-vap-likelihood-of-approval-2/ 2024-12-25T17:11:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-0228-brightgene-bio-medical-technology-colorectal-cancer-likelihood-of-approval-2/ 2024-12-25T17:11:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ava-6000-avacta-life-sciences-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:11:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hcw-9218-hcw-biologics-ovarian-cancer-likelihood-of-approval-2/ 2024-12-25T17:11:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/retatrutide-eli-lilly-and-co-type-2-diabetes-likelihood-of-approval/ 2025-01-19T16:56:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ttx-030-trishula-therapeutics-solid-tumor-likelihood-of-approval-2/ 2024-12-25T17:10:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-prostate-cancer-likelihood-of-approval/ 2025-01-19T16:55:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-0228-brightgene-bio-medical-technology-esophageal-cancer-likelihood-of-approval-2/ 2024-12-25T17:09:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ava-6000-avacta-life-sciences-soft-tissue-sarcoma-likelihood-of-approval-2/ 2024-12-25T17:09:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efineptakin-alfa-genexine-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval-2/ 2024-12-25T17:09:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nktr-255-nektar-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval-2/ 2024-12-25T17:08:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tunlametinib-binjiang-pharma-metastatic-colorectal-cancer-likelihood-of-approval-2/ 2024-12-25T17:08:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luveltamab-tazevibulin-sutro-biopharma-epithelial-ovarian-cancer-likelihood-of-approval-2/ 2024-12-25T17:08:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/futibatinib-otsuka-pharmaceutical-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval-2/ 2024-12-25T17:08:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/telisotuzumab-vedotin-abbvie-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:08:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zen-3694-zenith-epigenetics-solid-tumor-likelihood-of-approval/ 2025-01-19T16:53:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syd-3521-byondis-uveal-melanoma-likelihood-of-approval/ 2024-09-09T01:44:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vudalimab-xencor-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T17:07:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiragolumab-genentech-usa-solid-tumor-likelihood-of-approval-2/ 2024-12-25T17:06:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luveltamab-tazevibulin-sutro-biopharma-refractory-acute-myeloid-leukemia-likelihood-of-approval-2/ 2024-12-25T17:06:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relatlimab-bristol-myers-squibb-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval-2/ 2024-12-25T17:06:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lifileucel-iovance-biotherapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T16:52:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-refractory-acute-myeloid-leukemia-likelihood-of-approval-2/ 2024-12-25T17:05:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ft-819-fate-therapeutics-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-09-09T01:43:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efineptakin-alfa-neoimmunetech-solid-tumor-likelihood-of-approval-2/ 2024-12-25T17:05:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syd-3521-byondis-solid-tumor-likelihood-of-approval/ 2024-09-09T01:43:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval-2/ 2024-12-25T17:04:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vobramitamab-duocarmazine-macrogenics-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval-2/ 2024-12-25T17:04:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nktr-255-nektar-therapeutics-solid-tumor-likelihood-of-approval-2/ 2024-12-25T17:04:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luveltamab-tazevibulin-sutro-biopharma-relapsed-acute-myeloid-leukemia-likelihood-of-approval-2/ 2024-12-25T17:04:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-soft-tissue-sarcoma-likelihood-of-approval-2/ 2024-12-25T17:04:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval-2/ 2024-12-25T17:04:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alpelisib-novartis-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-19T16:44:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-metastatic-prostate-cancer-likelihood-of-approval/ 2025-01-19T16:44:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-dermatomyositis-likelihood-of-approval-2/ 2024-12-25T17:02:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-fallopian-tube-cancer-likelihood-of-approval-2/ 2024-12-25T17:02:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-likelihood-of-approval-2/ 2024-12-25T17:02:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ribociclib-succinate-novartis-glioblastoma-multiforme-gbm-likelihood-of-approval-2/ 2024-12-25T17:02:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pac-1-vanquish-oncology-solid-tumor-likelihood-of-approval-2/ 2024-12-25T17:02:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-ovarian-cancer-likelihood-of-approval-2/ 2024-12-25T17:02:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rvu-120-ryvu-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval-2/ 2024-12-25T17:02:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-kaposi-sarcoma-likelihood-of-approval-2/ 2024-12-25T17:01:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-chronic-inflammatory-demyelinating-polyneuropathy-cidp-likelihood-of-approval-2/ 2024-12-25T17:01:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-bladder-cancer-likelihood-of-approval-2/ 2024-12-25T17:01:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-metastatic-renal-cell-carcinoma-likelihood-of-approval-2/ 2024-12-25T17:01:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-marginal-zone-b-cell-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:01:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/capmatinib-hydrochloride-novartis-metastatic-melanoma-likelihood-of-approval/ 2025-01-19T16:42:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-b-cell-non-hodgkin-lymphoma-likelihood-of-approval-2/ 2024-12-25T17:01:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval-2/ 2024-12-25T17:01:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-merkel-cell-carcinoma-likelihood-of-approval-2/ 2024-12-25T17:01:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-prostate-cancer-likelihood-of-approval-2/ 2024-12-25T17:00:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-gastric-cancer-likelihood-of-approval-2/ 2024-12-25T17:00:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-basal-cell-carcinoma-basal-cell-epithelioma-likelihood-of-approval-2/ 2024-12-25T17:00:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval-2/ 2024-12-25T17:00:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-skin-cancer-likelihood-of-approval-2/ 2024-12-25T17:00:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval-2/ 2024-12-25T17:00:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lurbinectedin-jazz-pharmaceuticals-metastatic-biliary-tract-cancer-likelihood-of-approval-2/ 2024-12-25T16:59:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-metastatic-colorectal-cancer-likelihood-of-approval-2/ 2024-12-25T16:58:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval-2/ 2024-12-25T16:58:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval-2/ 2024-12-25T16:58:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erdafitinib-johnson-johnson-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T16:58:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-non-small-cell-lung-cancer-likelihood-of-approval-2/ 2024-12-25T16:58:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dabrafenib-mesylate-novartis-hairy-cell-leukemia-likelihood-of-approval-2/ 2024-12-25T16:58:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-pancreatic-cancer-likelihood-of-approval-2/ 2024-12-25T16:58:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval-2/ 2024-12-25T16:57:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-triple-negative-breast-cancer-tnbc-likelihood-of-approval-2/ 2024-12-25T16:57:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval-2/ 2024-12-25T16:57:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-lymphoblastic-lymphoma-likelihood-of-approval-2/ 2024-12-25T16:57:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgba-3055-beigene-solid-tumor-likelihood-of-approval/ 2024-04-19T00:12:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-26808-beigene-solid-tumor-likelihood-of-approval/ 2025-01-19T16:39:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adrx-0706-adcentrx-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-19T16:38:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adrx-0706-adcentrx-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T16:38:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adrx-0706-adcentrx-therapeutics-cervical-cancer-likelihood-of-approval/ 2025-01-19T16:38:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adrx-0706-adcentrx-therapeutics-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T16:38:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adrx-0706-adcentrx-therapeutics-breast-cancer-likelihood-of-approval/ 2025-01-19T16:38:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adrx-0706-adcentrx-therapeutics-ovarian-cancer-likelihood-of-approval/ 2025-01-19T16:38:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bg-136-marine-biomedical-research-institute-of-qingdao-solid-tumor-likelihood-of-approval/ 2024-04-19T00:12:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sevasemten-edgewise-therapeutics-becker-muscular-dystrophy-likelihood-of-approval/ 2024-06-14T01:18:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/absk-043-abbisko-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-19T16:37:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-rectal-cancer-likelihood-of-approval/ 2025-01-19T16:37:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-vulvar-cancer-likelihood-of-approval/ 2025-01-19T16:37:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/absk-043-abbisko-therapeutics-melanoma-likelihood-of-approval/ 2025-01-19T16:37:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/soquelitinib-corvus-pharmaceuticals-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-19T16:37:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203-immatics-melanoma-likelihood-of-approval/ 2024-07-05T01:21:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-023-shenzhen-xiankangda-life-sciences-endometrial-cancer-likelihood-of-approval/ 2024-07-05T01:20:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-023-shenzhen-xiankangda-life-sciences-thyroid-cancer-likelihood-of-approval/ 2024-07-05T01:20:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-023-shenzhen-xiankangda-life-sciences-esophageal-cancer-likelihood-of-approval/ 2024-07-05T01:20:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-023-shenzhen-xiankangda-life-sciences-pancreatic-cancer-likelihood-of-approval/ 2024-07-05T01:20:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-023-shenzhen-xiankangda-life-sciences-gastric-cancer-likelihood-of-approval/ 2024-07-05T01:20:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-023-shenzhen-xiankangda-life-sciences-solid-tumor-likelihood-of-approval/ 2024-07-05T01:20:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-023-shenzhen-xiankangda-life-sciences-prostate-cancer-likelihood-of-approval/ 2024-07-05T01:20:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-023-shenzhen-xiankangda-life-sciences-colorectal-cancer-likelihood-of-approval/ 2024-07-05T01:20:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-023-shenzhen-xiankangda-life-sciences-cervical-cancer-likelihood-of-approval/ 2024-07-05T01:20:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-023-shenzhen-xiankangda-life-sciences-breast-cancer-likelihood-of-approval/ 2024-07-05T01:20:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-023-shenzhen-xiankangda-life-sciences-lung-cancer-likelihood-of-approval/ 2024-07-05T01:20:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-023-shenzhen-xiankangda-life-sciences-ovarian-cancer-likelihood-of-approval/ 2024-07-05T01:20:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brexpiprazole-otsuka-pharmaceutical-post-traumatic-stress-disorder-ptsd-likelihood-of-approval/ 2025-01-19T16:37:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/na-831-biomed-industries-major-depressive-disorder-likelihood-of-approval/ 2025-01-19T16:36:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-deruxtecan-daiichi-sankyo-esophageal-cancer-likelihood-of-approval/ 2025-01-19T16:36:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/soquelitinib-corvus-pharmaceuticals-t-cell-lymphomas-likelihood-of-approval/ 2025-01-19T16:36:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T16:36:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cdx-585-celldex-therapeutics-solid-tumor-likelihood-of-approval/ 2024-04-19T00:05:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/upadacitinib-er-abbvie-oligoarticular-idiopathic-juvenile-arthritis-likelihood-of-approval/ 2025-01-19T16:36:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tovorafenib-day-one-biopharmaceuticals-craniopharyngioma-likelihood-of-approval/ 2025-01-19T16:36:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-19T16:36:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-deruxtecan-daiichi-sankyo-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-19T16:35:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-deruxtecan-daiichi-sankyo-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-19T16:35:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/binimetinib-pfizer-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-19T16:35:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lemzoparlimab-abbvie-follicular-lymphoma-likelihood-of-approval/ 2025-01-19T16:35:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-gastric-cancer-likelihood-of-approval/ 2025-01-19T16:35:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lemzoparlimab-abbvie-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T16:35:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexmedetomidine-bioxcel-therapeutics-alzheimer-s-disease-likelihood-of-approval/ 2025-01-19T16:35:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexmedetomidine-bioxcel-therapeutics-bipolar-disorder-manic-depression-likelihood-of-approval/ 2025-01-19T16:35:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T16:35:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-deruxtecan-daiichi-sankyo-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-19T16:35:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T16:34:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2025-01-19T16:34:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-revamps-eua-guidance-for-covid-19-monoclonal-antibodies/ 2023-12-21T16:29:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/sudo-raises-116m-to-advance-tyk2-programmes/ 2023-12-21T16:27:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-rejects-msds-gefapixant-for-chronic-cough/ 2023-12-21T11:53:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/genevoyager-opens-cdmo-facility/ 2024-06-07T13:51:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/calliditas-fda-approval-tarpeyo/ 2023-12-21T11:10:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-ocelot-bio-ascites/ 2024-01-08T21:34:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/gsk-license-hansoh-cancer-drug/ 2023-12-21T09:45:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ui-059-korea-united-pharm-reflux-esophagitis-gastroesophageal-reflux-disease-likelihood-of-approval/ 2024-01-03T07:27:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/meloxicam-fast-acting-viatris-post-operative-pain-likelihood-of-approval/ 2024-05-20T04:00:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nd-10-er-theialife-sciences-myopia-likelihood-of-approval/ 2024-03-19T00:11:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mabs-139-manhattan-biosolutions-solid-tumor-likelihood-of-approval/ 2025-01-20T17:06:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abatacept-biosimilar-dr-reddy-s-laboratories-rheumatoid-arthritis-likelihood-of-approval/ 2025-01-20T17:06:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-4524101-gsk-solid-tumor-likelihood-of-approval/ 2024-04-20T00:59:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gsk-4524101-gsk-breast-cancer-likelihood-of-approval/ 2024-04-20T00:59:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-787-abbvie-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-20T17:06:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-787-abbvie-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-20T17:06:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986458-bristol-myers-squibb-follicular-lymphoma-likelihood-of-approval/ 2025-01-20T17:06:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986458-bristol-myers-squibb-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-20T17:05:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kb-707-krystal-biotech-metastatic-melanoma-likelihood-of-approval/ 2025-01-20T17:05:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ocrelizumab-biosimilar-celltrion-relapsing-remitting-multiple-sclerosis-rrms-likelihood-of-approval/ 2024-04-20T00:59:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2025-01-20T17:05:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-20T17:05:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-metastatic-melanoma-likelihood-of-approval/ 2025-01-20T17:05:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-20T17:05:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-765845-boehringer-ingelheim-international-myocardial-infarction-likelihood-of-approval/ 2025-01-20T17:05:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fl-115-suzhou-forlong-biotechnology-solid-tumor-likelihood-of-approval/ 2025-01-20T17:05:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-932-abbvie-schizophrenia-likelihood-of-approval/ 2025-01-20T17:05:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/debio-4326-debiopharm-international-central-precocious-puberty-likelihood-of-approval/ 2024-04-20T00:58:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/caba-201-cabaletta-bio-lupus-nephritis-likelihood-of-approval/ 2025-01-20T17:05:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibi-343-innovent-biologics-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-20T17:05:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ibi-343-innovent-biologics-gastric-cancer-likelihood-of-approval/ 2025-01-20T17:05:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nido-361-nido-biosciences-kennedy-s-disease-spinal-and-bulbar-muscular-atrophy-likelihood-of-approval/ 2025-01-20T17:05:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/biological-162-yangshengtang-hepatitis-b-likelihood-of-approval/ 2025-01-20T17:05:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986406-bristol-myers-squibb-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-20T17:04:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986406-bristol-myers-squibb-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-20T17:04:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986406-bristol-myers-squibb-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-20T17:04:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986406-bristol-myers-squibb-metastatic-ovarian-cancer-likelihood-of-approval/ 2025-01-20T17:04:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986406-bristol-myers-squibb-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-20T17:04:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986406-bristol-myers-squibb-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-20T17:04:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986406-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2025-01-20T17:04:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986406-bristol-myers-squibb-bladder-cancer-likelihood-of-approval/ 2025-01-20T17:04:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986406-bristol-myers-squibb-gastric-cancer-likelihood-of-approval/ 2025-01-20T17:04:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/meningococcal-pentavalent-vaccine-sanofi-neisseria-meningitidis-infections-likelihood-of-approval/ 2023-12-21T03:00:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hc-7366-hibercell-renal-cell-carcinoma-likelihood-of-approval/ 2024-07-05T17:37:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hy-0102-shanghai-hyamab-biotech-solid-tumor-likelihood-of-approval/ 2025-01-20T17:04:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hy-0102-shanghai-hyamab-biotech-head-and-neck-cancer-likelihood-of-approval/ 2025-01-20T17:04:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hy-0102-shanghai-hyamab-biotech-liver-cancer-likelihood-of-approval/ 2025-01-20T17:04:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hy-0102-shanghai-hyamab-biotech-lung-cancer-likelihood-of-approval/ 2025-01-20T17:04:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ecc-5004-astrazeneca-type-2-diabetes-likelihood-of-approval/ 2025-01-20T17:04:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vmt-a-net-perspective-therapeutics-pheochromocytoma-likelihood-of-approval/ 2025-01-20T17:03:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aflibercept-biosimilar-celltrion-age-related-macular-degeneration-likelihood-of-approval/ 2025-01-20T17:03:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jskn-003-alphamab-oncology-bladder-cancer-likelihood-of-approval/ 2025-01-20T17:03:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vrdn-003-viridian-therapeutics-graves-ophthalmopathy-likelihood-of-approval/ 2025-01-20T17:03:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dr-0201-dren-bio-hematological-tumor-likelihood-of-approval/ 2025-01-20T17:03:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/shr-1819-jiangsu-hengrui-medicine-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2025-01-20T17:03:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bi-1569912-boehringer-ingelheim-international-major-depressive-disorder-likelihood-of-approval/ 2025-01-20T17:03:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ustekinumab-biosimilar-celltrion-psoriatic-arthritis-likelihood-of-approval/ 2025-01-20T17:03:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vx-103-vaxess-technologies-influenza-a-virus-h1n1-subtype-infections-likelihood-of-approval/ 2023-12-21T02:37:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tw-012r-time-therapeutics-alzheimer-s-disease-likelihood-of-approval/ 2025-01-20T17:03:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-hyaluronidase-human-recombinant-johnson-johnson-alzheimer-s-disease-likelihood-of-approval/ 2025-01-20T17:03:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ono-2808-ono-pharmaceutical-multiple-system-atrophy-msa-or-shy-drager-syndrome-or-multi-system-degeneration-likelihood-of-approval/ 2025-01-20T17:03:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mc-225-mc2-therapeutics-vulvar-lichen-sclerosus-likelihood-of-approval/ 2025-01-20T17:03:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sevasemten-edgewise-therapeutics-duchenne-muscular-dystrophy-likelihood-of-approval/ 2024-06-19T05:47:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vaxinia-imugene-liver-cancer-likelihood-of-approval/ 2024-09-09T04:48:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kine-101a-kine-sciences-rheumatoid-arthritis-likelihood-of-approval/ 2025-01-20T17:02:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pipe-307-janssen-pharmaceutica-relapsing-remitting-multiple-sclerosis-rrms-likelihood-of-approval/ 2025-01-20T17:02:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ersm-5404-hibercell-papillary-renal-cell-carcinoma-likelihood-of-approval/ 2024-09-09T04:48:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ersm-5404-hibercell-renal-cell-carcinoma-likelihood-of-approval/ 2024-09-09T04:48:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ersm-5404-hibercell-solid-tumor-likelihood-of-approval/ 2024-09-09T04:48:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ersm-5404-hibercell-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T04:48:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ersm-5404-hibercell-gastric-cancer-likelihood-of-approval/ 2024-09-09T04:48:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ersm-5404-hibercell-colorectal-cancer-likelihood-of-approval/ 2024-09-09T04:47:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sr-8541a-stingray-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-20T17:02:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/revumenib-citrate-syndax-pharmaceuticals-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-20T17:02:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/revumenib-citrate-syndax-pharmaceuticals-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-20T17:02:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trx-920-tairx-solid-tumor-likelihood-of-approval/ 2024-04-20T00:53:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/divozilimab-biocad-neuromyelitis-optica-devic-s-syndrome-likelihood-of-approval/ 2024-03-19T00:08:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ozuriftamab-vedotin-bioatla-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-20T17:02:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/admilparant-bristol-myers-squibb-pulmonary-fibrosis-likelihood-of-approval/ 2025-01-20T17:02:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vtp-200-barinthus-biotherapeutics-human-papillomavirus-hpv-associated-cancer-likelihood-of-approval/ 2023-12-21T01:56:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vtp-200-barinthus-biotherapeutics-cervical-intraepithelial-neoplasia-cin-likelihood-of-approval/ 2023-12-21T01:56:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vtp-200-barinthus-biotherapeutics-cervical-cancer-likelihood-of-approval/ 2023-12-21T01:55:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zasocitinib-takeda-pharmaceutical-psoriatic-arthritis-likelihood-of-approval/ 2025-01-20T17:02:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-20T17:02:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trgft-201-orca-biosystems-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2025-01-20T17:01:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tilt-123-tilt-biotherapeutics-sarcomas-likelihood-of-approval/ 2025-01-20T17:01:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apac-aplagon-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2025-01-20T17:01:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pmn-310-promis-neurosciences-alzheimer-s-disease-likelihood-of-approval/ 2025-01-20T17:01:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rostaporfin-tuhura-biosciences-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-20T17:01:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enitociclib-vincerx-pharma-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-20T17:01:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mecbotamab-vedotin-bioatla-pancreatic-cancer-likelihood-of-approval/ 2025-01-20T17:01:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-20T17:01:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/larsucosterol-sodium-durect-alcoholic-hepatitis-likelihood-of-approval/ 2025-01-20T17:01:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/razpipadon-cerevel-therapeutics-dementia-likelihood-of-approval/ 2025-01-20T17:01:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ompenaclid-succinate-inspirna-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-02-08T04:26:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-mural-oncology-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T04:45:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosifloxuridine-nafalbenamide-nucana-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/ 2025-01-20T17:01:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-mural-oncology-ovarian-cancer-likelihood-of-approval/ 2024-09-09T04:45:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosifloxuridine-nafalbenamide-nucana-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-20T17:01:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosifloxuridine-nafalbenamide-nucana-endometrial-cancer-likelihood-of-approval/ 2025-01-20T17:01:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosifloxuridine-nafalbenamide-nucana-esophageal-cancer-likelihood-of-approval/ 2025-01-20T17:01:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosifloxuridine-nafalbenamide-nucana-gastric-cancer-likelihood-of-approval/ 2025-01-20T17:00:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosifloxuridine-nafalbenamide-nucana-metastatic-melanoma-likelihood-of-approval/ 2025-01-20T17:00:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efruxifermin-akero-therapeutics-liver-cirrhosis-likelihood-of-approval/ 2025-01-20T17:00:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ccar-066-janssen-biotech-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-20T17:00:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ccar-066-janssen-biotech-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-20T17:00:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ccar-066-janssen-biotech-follicular-lymphoma-likelihood-of-approval/ 2025-01-20T17:00:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-melanoma-likelihood-of-approval/ 2025-01-20T17:00:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-leiomyosarcoma-likelihood-of-approval/ 2025-01-20T17:00:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-lung-cancer-likelihood-of-approval/ 2025-01-20T17:00:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-neuroendocrine-cancer-likelihood-of-approval/ 2025-01-20T17:00:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bexmarilimab-faron-pharmaceuticals-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-20T17:00:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-614-ensysce-biosciences-post-operative-pain-likelihood-of-approval/ 2024-03-19T00:07:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-06-19T05:42:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-06-19T05:42:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-small-intestine-cancer-likelihood-of-approval/ 2024-06-19T05:42:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pds-01adc-pds-biotechnology-colorectal-cancer-likelihood-of-approval/ 2024-06-19T05:42:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/finerenone-bayer-congestive-heart-failure-heart-failure-likelihood-of-approval/ 2024-09-09T04:44:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brolucizumab-novartis-proliferative-diabetic-retinopathy-pdr-likelihood-of-approval/ 2025-01-20T17:00:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/av-001-vasomune-therapeutics-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2025-01-20T17:00:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/capivasertib-astrazeneca-hormone-sensitive-prostate-cancer-likelihood-of-approval/ 2025-01-20T16:59:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/comment/the-curtain-closes-on-a-successful-world-investment-conference-in-new-delhi/ 2023-12-20T23:00:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tnx-1900-tonix-pharmaceuticals-holding-autism-spectrum-disorder-asd-likelihood-of-approval/ 2024-06-19T05:41:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-ovarian-cancer-likelihood-of-approval/ 2025-01-20T16:59:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tapinarof-dermavant-sciences-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2025-01-20T16:53:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivozanib-hydrochloride-aveo-pharmaceuticals-gallbladder-cancer-likelihood-of-approval/ 2025-01-20T16:52:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivozanib-hydrochloride-aveo-pharmaceuticals-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-20T16:52:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivozanib-hydrochloride-aveo-pharmaceuticals-neuroendocrine-cancer-likelihood-of-approval/ 2025-01-20T16:53:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivozanib-hydrochloride-aveo-pharmaceuticals-prostate-cancer-likelihood-of-approval/ 2025-01-20T16:52:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivozanib-hydrochloride-aveo-pharmaceuticals-pancreatic-cancer-likelihood-of-approval/ 2025-01-20T16:52:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/glepaglutide-zealand-pharma-short-bowel-syndrome-likelihood-of-approval/ 2025-01-20T16:52:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/radium-ra-223-dichloride-bayer-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-20T16:52:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pollinex-quattro-grass-allergy-therapeutics-seasonal-allergic-rhinitis-likelihood-of-approval/ 2025-01-20T16:52:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/surufatinib-hutchison-medipharma-non-rhabdomyosarcoma-likelihood-of-approval/ 2025-01-20T16:52:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/surufatinib-hutchison-medipharma-osteosarcoma-likelihood-of-approval/ 2025-01-20T16:52:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/surufatinib-hutchison-medipharma-ewing-sarcoma-likelihood-of-approval/ 2025-01-20T16:52:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/surufatinib-hutchison-medipharma-rhabdomyosarcoma-likelihood-of-approval/ 2025-01-20T16:52:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/surufatinib-hutchison-medipharma-lymphoma-likelihood-of-approval/ 2025-01-20T16:52:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-20T16:52:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tremelimumab-astrazeneca-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-20T16:52:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/collagenase-clostridium-histolyticum-endo-international-fasciitis-likelihood-of-approval/ 2025-01-20T16:52:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tofacitinib-citrate-pfizer-systemic-onset-juvenile-idiopathic-arthritis-still-disease-likelihood-of-approval/ 2025-01-20T16:52:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sarilumab-regeneron-pharmaceuticals-systemic-onset-juvenile-idiopathic-arthritis-still-disease-likelihood-of-approval/ 2024-09-09T04:42:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-angiosarcoma-likelihood-of-approval/ 2025-01-20T16:51:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/aclaris-chops-workforce-and-shifts-lead-drugs-focus-to-cancer-indications/ 2023-12-20T17:56:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vax-24-vaxcyte-net-present-value/ 2024-05-16T02:09:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ulixacaltamide-praxis-precision-medicines-net-present-value/ 2024-06-13T18:49:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amlitelimab-sanofi-net-present-value/ 2024-07-02T02:04:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azenosertib-zentalis-pharmaceuticals-net-present-value/ 2024-12-13T02:51:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tn-301-tenaya-therapeutics-net-present-value/ 2024-05-16T02:07:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oric-944-oric-pharmaceuticals-net-present-value/ 2024-06-13T18:53:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mrna-1010-moderna-net-present-value/ 2024-07-02T02:09:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rhenium-186re-obisbemeda-plus-therapeutics-net-present-value/ 2024-05-16T01:59:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/revumenib-syndax-pharmaceuticals-net-present-value/ 2024-06-13T18:48:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aficamten-cytokinetics-net-present-value/ 2024-06-13T18:48:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctx-130-crispr-therapeutics-net-present-value/ 2024-07-02T02:08:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/transcon-cnp-ascendis-pharma-net-present-value/ 2024-07-02T02:08:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axitinib-ocular-therapeutix-net-present-value/ 2024-06-13T18:48:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vudalimab-xencor-net-present-value/ 2024-12-13T02:52:34+00:00 daily 0.2